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PREFACE
This research project was supported by NASA under a cooperative
agreement between the NASA Johnson Space Center and the University of
Houston-Clear Lake (NCC 9-16, Activity IM.5). The conclusions
[and/or interpretations] are those of the Center for Space and
Advanced Technology.
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SPACE AND BIOTECHNOLOGY: An Industry Profile@
I. EXECUTIVE SUMMARy
This report presents the results of a study conducted by the
Center for Space and Advanced Technology (CSAT) for NASA-JSC. The
objectives were to determine the interests and attitudes of the U.S.
blotechnology industry toward space blotechnology and to prepare a
concise review of the current activities of the blotechnology industry.
In order to accomplish these objectives, two primary actions were
taken. First, a questionnaire was designed, reviewed and distributed
to U.S. biotechnology companies. Second, reviews of the various
biotechnology fields were prepared in several aspects of the industry
(Biotechnology Business, Agriculture, Medicine and Veterinary
Medicine). For each review, leading figures in the field were asked
to prepare a brief review pointing out key trends and current industry
technical problems. The result is a readable narrative of the
blotechnology industry which will provide space scientists and
engineers valuable clues as to where the space environment can be
explored to advance the U.S. biotechnology industry.
The questionnaire was designed for a two-tiered response system.
The first tier dealt with the industry's level of awareness of basic
space program activities and interest in pursuing space
biotechnology. The second tier was more comprehensive and dealt with
a wider range of capabilities and attitudes toward space biotechnology.
To enhance the overall study, the primary study team assembled an
advisory group consisting of individuals on the front lines of both
research and business development. This group helped design the
questionnaire and suggested additional industry contacts. Individuals
in the advisory group and certain other specific experts were also
asked to prepare review articles on various phases of the industry.
According to the Arthur Young High Technology Group report,
"Biotech '88: Into the Marketplace," the O.S. biotechnology industry
has a universe of over 900 corporations and is still growing at 10%
per year. Of these 900, approximately 400 companies can truly be
identified as primarily involved in biotechnology. The gross
expenditure for this industry is some $17 billion, while revenues are
about $13 billion or a net loss of $4 billion. One reason why
expenses are so heavy is that biotechnology is research driven.
Approximately 27% of all expenses are for R&D with an additional 26%
spent to acquire technology through purchase. This 53% compares with
the normal industry range of 2-7%.
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Thus the industry is very dynamic and is continually seeking
competitive advantages. This is the environment which the
questionnaire on space biotechnology penetrated. Two hundred and four
U.S. firms were selected out of the biotechnology universe
representing a broad array of size and product orientation. Roughly
one third of those responding had research budgets below $I0 million,
one-third $i0-i00 million and one-third over _I00 million.
Some 21% of those surveyed responded to the first tier, while 10%
responded to the second tier--the more detailed part. Of the
respondents, 83% felt that space research for space-based processes
was of value to the biotechnology industry. Further, 54% would llke
to participate in space blotechnology through workshops, user groups,
and cooperative research programs. Another important response was
that 69% felt that the Space Station would provide support for the
U.S. blotechnolo&y industry.
When asked what type of information was needed to encourage their
participation, the following answers were most frequently provided:
a bibliography of publications providing results of past space
blotechnology research and details of the space environment
relative to space biotechnology.
• a compendium of space biotechnology resources available
• cost and time information for planning experiments
• evidence of tangible benefits of space blotechnology
The overall impression gathered from the questionnaire, the
bioteehnology review articles, and telephone interviews is that the
biotechnology industry is a rapidly growing field which is research
and development oriented. Remarkable applications for improved plants
and animals have been developed in recent years to complement past
progress in the pharmaceutical area. Research, however, is costly and
difficult to sustain for any private enterprise, and, therefore, moet
are scrambling for funds and new ideas to increase their competitive
edge. Thus, the possibility of NASA, private industry, and university
cooperative research in these areas is attractive.
While there is considerable interest in space biotechnolo8Y, the
industry is not well informed of the space environment or applicable
space biological research. As was identified in the questionnaire, it
will be important to provide the industry with basic materials and
workshops on space and its potential for biotechnology. Conversely,
stronger lines of communication for NASA must also be established so
that they understand the needs of the btotechnology industry.
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II. INTRODUCTION
The objective of this study was the development of a U.S.
blotechnology industry profile which describes the Industry's
technology needs, outlines trends in research and technology which may
benefit from space research, and determines corporate interest in
space blotechnology research. A major segment of the U.S.
biotechnology industry has been surveyed in this study. Two hundred
and four U.S. blotechnology companies were requested to complete a
biotechnology questionnaire. Two mailings and selected telephone
follow-up were made. Twenty three percent of the companies responded
by completing the questionnaire. Thls report provides an overview of
the blotechnology field and summarizes the results of the study with
recommendations for future NASA activities.
The Center for Space and Advanced Technology, under a subcontract
to the University of Houston at Clear Lake, is developing a long-range
strategic plan to assist NASA in structuring a program to promote the
utilization of the Space Station for commercial purposes. This plan
will assist NASA management in developing a combination of policies,
objectives and programs that will ensure that United States
corporations have the opportunity to fully exploit the potentials of
commercial space enterprises. Industries which may be interested in
space blotechnology are being asked their perception of the space
station and their interest in research in the microgravlty environment.
A. Blotechnolo_ Overview
In the past 15 years, dramatic new developments in the ability to
select and manipulate genetic material have generated interest in the
medical, agricultural, and industrial uses of living organisms and
their products. A major technology revolution is occurring in the
United States and in foreign countries. Biotechnology is having a
major impact on traditional American industry as a continuous stream
of novel technologies create new business opportunities.
Btotechnology represents a breakthrough on a par with that of
computers and micro electronics. It is a field that is projected to
expand from current levels of $750 million per year to $40 billion per
year by the year 2000. The report, "Commercial Biotechnology, an
International Analysis," published in 1984 by the Office of Technology
Assessment, gives the following description:
_J_.qlg_Y, broadly defined, includes any technique that uses
living organisms (or parts of organisms) to make or modify
products, to improve plants, or to develop microorganisms for
specific uses. Biological processes and organisms have been used
with great success throughout history and have become increasingly
sophisticated over the years. Since the dawn of civilization,
people have deliberately selected organisms that improved
agriculture, animal husbandry, baking and brewing. More recently,
a better understanding of genetics has led to more effective
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application of traditional genetics in such areas as antibiotics
and chemical production. The novel techl%iques used in
blotechnology are extremely powerful because they allow a large
amount of control over biological systems.
Recombinant DNA CrDNA) techno!oRY, one of the new techniques,
allows direct manipulation of the genetic material of individual
cells. The ability to direct which genes are used by cells
permits more control over the production of biological molecules
than every before. Recombinant DNA technology can be used in a
wide variety of industrial sectors to develop microorganisms that
produce new products, existing products more efficiently, or large
quantities of otherwise scarce products. This technology can be
used to develop bacteria that degrade industrial wastes or new
strains of agriculturally important plants. Cell fusion (the
artificial joining of cells) combines the desirable
characteristics of different types of cells into one cell. This
technique has been used to incorporate in one cell, the traits of
immortality and rapid proliferation from cancer cells with the
ability to produce useful antibodies from specialized cells of the
immune system. The cell llne resulting from such a fusion, known
as a hybrldoma, produces large quantities of monoclonal antibodies
(MABs), so called because they have been produced by the progeny,
or clone, of a single hybridoma cell. MABs are demonstrating
great potential in the diagnosis and treatment of disease and in
the purification of proteins. The commercial success of specific
industrial applications of rDNA and cell fusion techniques will
hinge on bioprocess engineering.
Bloprocess technoloRY, though not a novel genetic technique, is
the application of biological methods of production to large-scale
industrial use. Many industrial biological syntheses at present
are carried out in single batches, with small amounts of products
being recovered from large quantities of cellular components,
nutrients, waste products, and water. Recent improvements in
techniques for immobilizing cells or enzymes and in bioreactor
designs, for example, are helping to increase production and
facilitate recovery of many substances. Additionally, new genetic
techniques can aid in the design of more efficient bloreactors,
sensors and recovery systems. In the next decade, competitive
advantage in areas related to biotechnology may depend as much on
developments in bioprocesslng engineering as on innovation in
genetics, immunology and other areas of basic science.
The same technologies that yield commercial products will also
provide new research tools. The new genetic technologies
described above have ignited an explosion of fundamental
knowledge. The widespread use of rDNA and cell fusion techniques
in the investigation of a wide variety of biological phenomena in
plants, animals, microorganisms, and viruses highlights the impact
of these technologies on basic science research and the advances
in fundamental knowledge that they make possible. This new
knowledge in return, may reveal new commercial applications.
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The industrial applications of biotechnology in the next ten years are
likely to occur in pharmaceuticals, veterinary sciences and agriculture,
and specialty chemicals. Subsequent chapters in this report will provide
field survey reports on the application in medicine, agriculture, and
veterinary biotechnology. In the vharmaceutical field, biotechnology is
being used for the production of proteins such as insulin and interferon;
antibiotics for treating patients; diagnostics; and vaccines for bacterial
and viral parasitic diseases. In veterinary medicine products are being
developed similar to those being developed in the pharmaceutical industry
with animal vaccines of great economic significance. In the svecialty
chemicals and food additives area, possible applications include
improvements in existing bioprocesses, such as the production of amino
acids, vitamins and steroid compounds. Biotechnology may provide single or
shorter production steps than those complex multi-step production processes
currently used. In plant agriculture, some important traits of plants,
including stress-resistance and pest-resistance appear to be rather simple
genetically, and it may be possible to transfer these traits to important
crop species in the next few years. Other traits such as increased growth
rate and increased photosynthetic ability are genetically more complex and
it is likely to take years to develop and field test plants with these new
traits. Environmental _ of biotechnolo_y include mineral
leaching and metal concentration, pollution control, toxic waste
degradation, and enhanced oil recovery.
Commodity _, which are now produced from petroleum feedstocks,
could be produced biologically from biomass feedstocks such as cornstarch
and lignocellulose. In the area of bioelectronics, biotechnology could be
used to develop improved biosensors or new conducting devices called
biochips. Sensors that use enzymes for detecting specific substances are
available now. However their use is limited by the narrow range of
substances they detect and by their temperature instability. Biotechnology
could be instrumental in the development of more versatile sensors that use
enzymes or MABs. Better sensors would be especially useful in the control
of industrial bioprocesses. Biotechnology may also make it possible to
construct devices that use proteins as a framework for molecules that act
as semiconductors. The anticipated advantages of these biochips are their
small size, reliability, and the potential for self assembly. The
production of biochips is one of the most distant applications of
biotechnology.
B. Locations of U.S. Biotechnoloev Comvanies
The highest density of biotechnolosy firms in the U.S. is in the San
Francisco Bay and Boston areas around the excellent universities in these
areas. Other concentrations include: Seattle, Los An6eles, and the
eastern seaboard from Connecticut to Virginia. The Carolinas, Ceor|ia,
Florida and Texas have a lesser density of biotechnology firms. Figure 1
shows the number of biotechnology firms by major Certified Metropolitan
Statistical Areas (CMSA) for 1987. In the report-figure vs. the
explaining-figure, the Northeast is not included.
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This chart was prepared by The Baltimore - Washington Common Market,
using data from "Biotech '88: Into the Marketplace," Arthur Yo._ug High
Technology Group. The survey universe was 1,054 firms, with the
remaining 471 distributed across the U.S. The Southwest is lagging
behind the rest of the country.
Flgum I: Number of B_ Flmm
by gq(w CMSA --- 1987
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C. Research and Develovment in Biotechnolo=y
The Congressional Office of Technolosy Assess=ent has recently
compiled a report on the rapid progress of the biotechnololy industry.
This report surveyed some 349 companies; large and small. The reported R
& D spendtn_ for 1987 was broken down into research areas co=parin_ small
biotechnolo&y firms, with large firms with biotechnolo&y interests.
Overall, in 1987 some $2 billion were spent on biotechnolosy by the
private sector. Table 1 outlines the various cate&ories of research
spending for the btotechnology industry, while Table 2 outlines Federally
Funded Biotechnology Research for 1985.
R & D Spending by Biotechnology Companies
Where the Money Is Being Spent
The Drwate sector soent aOout S2 billion on Oiotecnnology reselrcn
anO aevePooment _n 1987. Tr_e numOer of companies ,nvolvecl in eacrl
primary research segment is _n parenmeses: Collar values are ,n
millions.
Ulotech OtlJlef Larp
Research Area Commlmes * ComlMnles *
Drugs $252 _63) S206 114)
Diagnostics 216 (52) 86 (6)
Chemicals 84 (20) 168 (11 )
Plant agriculture 96 I24) 104 (7)
Animal agriculture 72 (19) 64 _4)
Soeoal,zeO chemicals 144 (34) 32 (2)
Waste ctsoosatltrealment 12 (3) 16 (I)
ECluloment 48 (12) 16 (1)
Cell culture 24 (5) 16 (1)
OiverslheO/otl_er 264 (44) 88 (6)
Total: 1.200 (2961 800 (53)
"From a samolmg o1349 companNl$ The I_OleCn companNl$ Sl_ln¢l at tillS180 OMCllnl
Of metr ,esellrcn ano Oeve*OOment on Oiotecrlnoto_y: me large complmtes Sl_lnCl at
Jeas! 20 _)ercent
Source: Othce of Tect_olocgy AlleSlrne.'w
The New Y_rk Times, July it. i_
TABLE 2: Federally Funded BiotechnolosY Research (1985)
Total R&D Btotech
Research
Asricultural Research Service
Cooperative State Research
Environmental Protection Asency
FDA
National Institute of Health
NSF
469.7 24.5
284.3 48.4
320.4 1.5
82.0 2.6
4824.4 1849.5
7325.4 2005.1
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III. STUDY PLAN
The purpose of this study was to develop a biotechnology industry
profile which describes current industrial technology needs,
identifies trends in research and technology which might benefit from
space research, and determines corporate interest in space
biotechnology research.
A. Study Objectives
l, To determine industry's understanding and expectations about
NASA's plans for conducting biotechnology and space biology
research in the Space Station.
2. To determine industry's perception about NASA activities to
encourage and assist private enterprise in space.
1 To determine what type of information would be useful to
blotechnology corporations to assist them in becoming active
participants in the commercial utilization of space.
, To assess the blotechnology corporate understanding of the
space environment, sciences, and technology.
. To determine the sensitivities of bioteclmology companies
about entering into collaborative relationships with NASA,
universities, and other biotechnolo&y companies.
. To determine if any company funds are currently being
committed to space related biotechnology research.
, To assess the key trends and future events which might impact
Industry's decision to enter into space related research
activities, and the type of ground and flight research needed
to fulfill critical biotec_lology needs to stimulate
industrial participation in the Space Station Program.
For the purposes of this study, Blotechnology covers the following
areas:
.Bioprocessing
•Cell/Tissue Culture
.Enzymology
.Fermentation
•Hybridoma (Cell Fusion)
•Large Scale Purification
•Process Monitoring and Control
.Purification/Separatlon
•Recombinant DNA
.Sequencing
.Synthesis
B. General Description of Study Plan
Methodology: The study plan was developed to utilize an industry
questionnaire (see Appendix A). Initially, plans were made to make
limited visits to selected biotechnology companies. Plans for these
visits were deleted from the program. Funding limitations precluded
the desired number of visits and it was felt that a well designed
questionnaire should produce the information needed. It was decided
that telephone calls would be made as a substitute for the corporate
visits. Ten percent of those companies who did not respond to the
first mailing were called to answer questions and to encourage
completion of the written questionnaire. To assist in the
development of uniform information, a telephone check list was
developed. Several of the company executives indicated that their
company did not take part in this type of study, nor did they
complete these types of questionnaires. Two companies indicated that
they would complete the questionnaire as a result of the telephone
conversation. One company executive stated that his technical staff
did not feel that the space environment could help with their
research programs. Another company officer indicated that he had a
problem understanding how the space environment related to his
technical problems, although this individual was aware of the
McDonnell Douglas electrophoresis flight experiments and the attempts
to grow crystals in space. Several people indicated an interest in
the final report. Many companies had administrative or secretarial
personnel return the telephone calls. It was obvious from these
telephone calls that the executives of biotechnology companies were
extremely busy and did not have time to let discussion of space
biotechnology interfere with their business.
A program management plan and schedule were developed to implement
this study. Payload Systems, Inc. was subcontracted as a study team
member to conduct a preliminary analysis of industry R & D in space
related biotechnology corporations. Results of the Payload Systems,
Inc. effort were submitted to NASA in March 1988. The University of
Houston Clear Lake provided biotechnology literature surveys.
Results from this effort are included in the bibliography (Appendix
B). The study schedule was established at the start of the project.
The final schedule lists the scheduled date and the actual completion
dates. This schedule was reviewed with the NASA technical monitor
during study review meetings. The completion of this final report
was delayed to include more technical information and a bibliography.
C. Or)anization
A StudyManagement Te_._amwas established to plan the study
program, develop a questlonnaire, conduct a telephone survey,
organize an industry workshop, and prepare the final reportn
of the Study Management Team were:
Members
Biotechnology Study Manager: Richard S. Johnston, Senior Advisor
Center for Space and Advanced Technology
Project Director: Peter C. Bishop, Ph.D.
University of Houston-Clear Lake
Study rlanager: Michael J. Svegliato
NASA/Johnson Space Center
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Technical Advisor: David J. Norton, Ph.D., Director, STARCenter
Houston Area Research Center
Technical Advisor: Baldwin H. Tom, Ph.D., Associate Director,
Bioprocessing Center, UT Health Science Center at Houston
(Present address: American Leadership Forum)
An Advisory Panel was established to provide professional review
of the overall study. Specific responsibilities included: review
industrial questionnaire, assist in industry survey and mailing list,
provide personal contacts, and review final report, t,lembersof the
Advisory Panel were:
Saul Kit, Ph.D., Biochemical Virology, Baylor College of Medicine
Robb Moses, M.D., Department of Cell Biology, Baylor College of
r_edicine
Robert Stone, M.D., Institute of Biosciences and Technology, TN_U
Peter Ulrich, Biosciences Corporation of Texas
D. List of Companies
A mailing list of companies for distribution of the questionnaire
(Appendix C) was made from two primary sources:
l) Sixth Annual GEN Guide to Biotechnology Companies,
November/December 1987, Genetic Engineering News, 1651 Third Avenue,
New York, NY I0128. This listing is an annual publication of
Genetic Engineering News. It provides a listing of 522 companies in
24 countries. The listing provides information including Chief
Executive Officer, Research Officer, principal technologies and major
products. Only the U.S. company listings were used in this study
(Appendix C). Data on companies surveyed is in Appendix D.
2) Payload Systems, Inc. Study: This study provided a
preliminary analysis and overview on the U.S. biotechnology
industry's research trends and gave an initial mailing list for the
biotechnology study questionnaire (Appendix A). An executive summary
of the Payloads Systems, Inc., "Analysis of Industry R & D in
Space-Related Biotechnology", is incuded in this report in Section V:
HISTORICAL PERSPECTIVES: SPACE BIOTECHNOLOGY RESEARCH.
-II-
E. Questionnaire
A two part questionnaire was prepared and reviewed by the Advisory
Panel in December 1987 (Appendix A). The study questionnaire and
planned schedule were approved by the NASA-Johnson Space Center study
manager on December 30, 1987. A listing of over 200 U.S.
blotechnolo&y companies was developed from the Payload Systems report
and other sources (Appendix C). This listing was reviewed with the
Advisory Panel and NASA. Efforts were made to develop a llst of key
technical personnel within as many companies as possible. Members of
the panel made suKEestlons for this key personnel llst. To increase
the industry responses, two mailin&s were made. The first on March
25, 1988 and the second on Aprll 11, 1988. Telephone follow-up calls
were made during the month of April using a check llst. Summary data
from the questionnaires was entered onto a computer by the staff at
the Houston Area Research Center. Data from the questionnaire is
contained in Section IV of this report. An industry workshop may be
held in the Fall of 1988 to review the study results and to discuss
future activities in space biotechnoloEy.
-12-
IV. QUESTIONNAIRE RESULTS
A. Summary of Data from Questionnaire
The questionnaire was initially mailed to some 204 corporate
officers representing a wide range of biotechnology firms in the
United States. This mailing was repeated after a three week interval
to those firms which had not responded to the first mailing. The
total response from both mailings was 46 or 23 percent.
This percentage is relatively high, especially considering the
intensity of effort at most biotechnology firms trying to create
successful enterprises. This indicates that despite the financial
pressure on these firms, there is a high level of interest in space
and its possibility for obtaining new knowledge which might provide a
competitive advantage.
The questionnaire was designed in two parts. The first part was
the front page and was largely designed with short-answer questions to
encourage participation. All responders filled in this portion of the
survey except one. The second part was longer and delved into more
subjective aspects of their business and their attitudes regarding
collaboration with NASA and others. Thirty five percent (35%) of the
respondents filled out the entire questionnaire.
B. Analvsls of Information
PART I.
Q I. Who are you?
The respondents were drawn from the upper ranks of each
corporation. Some 92% listed titles of President, Vice President,
Director or Manager. The balance were research scientists or market
analysts for their corporations.
Q 2. Are you familiar with NASA's Space Programs?
Knowledgeable
a) Space Shuttle 46%
b) Space Station 24
c) Space Blo & Biotech ii
d) Commercial Programs 7
Some Not
Knowledge Familiar
50% 2%
63 ii
74 13
59 33
The results show that there is general awareness of the Space
Shuttle and the Space Station but considerably less knowledge about
the commercial programs and the biological and biotechnological
aspects of NASA's activities. 0nly 7% felt that they were
knowledgeable about the commercial programs. Further, two-thlrds
checked at least one box requesting additional information concerning
these programs. The most frequent request was for information
regarding biological and commercial programs.
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Q 3. Are you familiar with the Space Environment?
Some Not
Knowledgeable Knowled_ F_millar
a. Microgravlty 22% 63% 13%
b. Vacuum 24 59 13
c. Space Radiation 13 50 33
The question shows that there is a great deal less understanding
of the value of the space environment than the 8eneral aspects of the
major space programs. Seventy-six percent indicate only some
knowledge or no knowledge of microgravity. This aspect of the space
environment is likely to be the key asset in space biotechnolo&y.
Q 4. Is there value in space research for the Biotech Industry?
Yes _o
a. Space Research for Space-based Processes 83%
b. Space Research for Earth-based Processes 74
c. Commercial Biotechnology Use of Space 59
d. Overall Space Blotechnology 63
13%
22
37
30
Overall this question implies a substantial belief that there is
value in space based research for the biotechnolo&y industry. By a
ratio of six to one, respondents believed that research in space for
space based processes was of value to the industry. To a lesser, but
still significant degree, research in space for earth based processes
was held to be of value. It was less clear that there would be value
in space based commercial uses. Overall by a two to one margin, space
biotechnology was considered to be of real value to the industry.
Q 5. Would you like to participate in Space Biotechnology?
Yes 54% No 4__ If yes, indicate possible interests:
a. Workshops 33%
b. User Group for Space Biotechnology 20
c. Cooperative Research with NASA 33
d. Cooperative Research with Univesities 20
e. Other 7
PART II.
Q 9. NaJor Corporate Technologies
There was & wide array of technologies listed under this
question. However, several appeared quite frequently. Those included:
.rDNA
•Monoclonal Antibodies
•Cell and Tissue Culture
•Immuno assays (immunology)
•Vaccines and pharmaceuticals
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Q I0. Najor Products
Again, this question brought out a long list of products and
services provided by these firms. For the smaller firms, many times
the technologies listed above are the products and services of the
corporation. For the larger firms, many technologies come together to
form a family of products. Thus for a small firm, cell sorting is the
technology and the product. For a larger firm, immunology and
monoclonal antibodies may lead to important antigens and even
pharmaceuticals.
Q Ii. Is your Company a part of any existing joint venture?
Some 37% indicated that they were a part of joint ventures.
Several indicated that there were too many to llst while others were
not involved.
Q 12. Company Resources
A very even distribution of companies responded. Thirty one
percent indicated that their research budgets were in excess of $i00
million. Twenty percent had research budgets between $I0 and $i00
million, while 37% had budgets less than $i0 million. Interestingly,
none of the respondents indicated any current budget devoted to space
blotechnology efforts.
Q 13. Company understanding of U.S. CoHnercial Space Programs.
Aware Not Aware
a) McDonnell-Douglas Electrophoresis
b) 3M Protein Crystal Studies
c) Space Industries Inc. - Industrial
Space Facility
49% 49%
31 69
27 73
To a large degree, the biotechnology industry is not aware of the
related programs and opportunities for space biotechnology.
Q 14. Do you envision that the Space Station will provide support for
the Biotechnology Industry? Yes 69% No 28%
The industry believes that the space station will support
blotechnology.
Q 15. What are the most difficult technologies facing the industry?
From the listing of technology difficulties the following were
most often mentioned: (frequencey ordered)
•Scale and reproducibility
•Separation and purification of cell products and biologicals
•Cell blology-control and gene expression
•Clinical studies
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Q 16. What type of information or scientific data is needed to
encourase participation?
In this case, there was a very clear voice as to what was needed:
(frequency ordered)
•A bibliography or publications on:
-past experience in space blotech
-space environment including microgravity
•Resources available for space blotechnology
•Cost information
•Evidence of tangible benefits (a success)
Q 17. What are the key trends and future events which may impact
space biotechnology?
The answers to this question are not well focused and it is
difficult to summarize the results. The most consistent answer with
respect to industry was that a clear demonstration of success in the
field would stimulate a great deal of interest.
Q 18. Suggested areas of research for RASA to pursue.
• Clonlr4 efficiency in microsravity
• Tissue culture growth in mlcrogravity
• Separation in microgravlty
• Cell productivity in space
• Freeze drying
Q 19. Would you consider forming a Joint venture to pursue
Biotechnolosy in space?
Fifty-seven percent indicated that they would consider forming a
Joint venture in space.
Q 21. Would you be willing to attend a workshop in Houston to review
this questionnaire and space biotechnolosy?
Fifty-seven percent indicated that they would be willing to attend
a workshop.
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C. General Comments
It is clear from these results that the industry needs information
before it can make informed decisions about space blotechnology.
Except for the pharmaceutical field, the blotechnology industry is a
young one striving to use new technologies and discoveries in
business. In this very competitive industry, things change rapidly.
As such, they are not generally aware of commercial space
opportunities or the existing work going on in NASA. There is,
however, a prediposition to believe that the Space Station and the
civil space program will be a resource for blotechnology in America.
The U.S. biotechnology industry already participates in joint
ventures and appears willing to participate in cooperative activities
with NASA and universities especially if the intellectual property
issues can be worked out to provide a competitive advantage.
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V. HISTORICAL PERSPECTIVES; SPACE BIOTECHNOLOGY RESEARCH
Payload Systems, Inc.
This review focuses on studies conducted aboard United States
spacecraft and is presented to provide a background showing the
limited biotechnology experiments flown to date. This perspectlve
serves not only to illustrate that few studies are available but also
to underscore our understanding that the planning for future
experimentation will require design input from both NASA and the
blotechnology practitioners. With the limited availability of
space-based experimentation, we must optimize each future flight
opportunity, and target studies not possible on Earth, and/or those of
near term economic benefit.
Space-based Biolo_!ca_ Research
•Manned space flights for over 25 years.
•Biological payloads begun in the 1960's.
•Manned Skylab experiments (1972-1974): Biological and
blotechnology experiments, including studies on antigen-
antibodies and cell culture growth.
•Space shuttle and space lab studies (from 1981). Focus on
bloprocesslng, llfe sciences, and materials sciences.
Recent Space-based BiotechnoloRY Research
• Btoseparattons using electrophoresis, potential use in isolation
of rare cells.
• Protein crystallization, potential use in pharmaceuticals and
electronics.
• Cell physiology, potential in exploiting cell product synthesis.
Prelude to space bioreactor use.
B_oseoaratlons
The most ambitious efforts to exploit microgravity for molecular
purification are the electrophoresls studies. In 1971, a zonal
electrophoresis experiment was flown aboard Apollo 14. The study
revealed a significant problem in separation process by the dominance
of electroosmotic flow in space. This separation technology was
re-flown on Apollo 16, Apollo-Soyuz, and STS-3. During Skylab
flights, Isotachophoresls experiments with hemoglobin, red cells, and
ferrltln were performed. The first flight using free-flow
electrophoresis hardware took place in 1982 on STS-3. Subsequently,
industry took an increased interest in the concept. NcDonnell Douglas
Aeronautics and Astronautics Corporation (MDAC) developed a continuous
flow electrophoresis system (CFES) for experimental use in the middeck
of the space shuttle. The equipment has been tested on seven flights,
resulting in the demonstration that up to 700 times more protein per
unit time could be run through the CFES than was possible on Earth.
The purification factor of four achieved on Earth with a mixture of
proteins was maintained in the microgravity experiments. A production
run attempted in the last flight in 1985 produced significant amounts
of the hormone, erythropoietin, an important drug for stimulating
blood cell formation. However, the product was contaminated by
bacterial endotoxin. Future flights will be needed to develop
measures to overcome the contamination problem.
One area which might be exploited to advantage in microgravity is
the use of CFES for the isolation of rare cells from large cell
populations. The isolation of the growth hormone producing cells from
the pituitary, or the insulin producing cells from the pancreas, might
be worthwhile candidates. The cell or subcellular orsanelle focus for
microgravity separation should be seriously considered, since the
focus on the mlcrogravity purification of proteins is now difficult to
Justify. There is presently rapid development of large-scale, high
purity separation techniques for proteins by the research and
development communities. In addition, genetically engineered protein
production is further diminishing the drive to seek mlcrogravity
protein production.
The USSR has also been operating electrophoresis devices on the
Salyut space station. The system, named Kashtan, incorporates one
separation chamber of 1.2 m and can hold up to 70 ml. The experiments
have demonstrated improvements in throughput of several orders of
magnitude over &round-based equipment, with efficiency factors between
10-15. USSR collaborative activities are taking place with France
(free-flow electrophoresls) and Germany (molecular sieve electro-
phoresis). The Soviets have offered space on their MIR space station
for commercial processing of materials.
Protein Crystallization
The knowledge of the structure of certain proteins can lead to the
rational design of drugs and the creation of analogs for antivlral,
chemotherapy, Immunosuppresslve, neurological, and hormonal appli-
cations. Any technique that will enhance the definition of protein
structures is of considerable interest to the pharmaceutical,
blotechnologlcal, and agricultural communities. X-ray crystallography
is a powerful method for determining the three-dlmenslonal structures
of complicated biological molecules. Crystallographic studies of
proteins and nucleic acids have played key roles in establishing the
structural foundations of molecular biology. More recently,
crystallographic studies of biological macromolecules have become of
considerable interest to the biotechnology industry, as promising
tools in protein engineering and drug desisn. 1 Crystallography, to be
effective, requires that relatively large crystals be grown in order
to have sufficient amounts of the same material to use in determining
molecular structure. The growth of such crystals occurs when the
molecules are staSillzed and allowed to spontaneously assemble by weak
molecular interactions. In the presence of a gravitational field,
such weak interactions are overwhelmed by stronger macroscopic
influences, such as convection and sedimentation forces.
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Many techniques are used in protein crystallography. These are
well described in McPherson's paper. 2 According to McPherson, the
crystallization of proteins is actually more art than science. Among
the most popular microgravity techniques is the hanging drop 1,3
method, in which a drop of a few microltters of a solution of protein,
buffer and salt (or often polyethylene glycol) is hung and left to
equilibrate. During the associated evaporation of the solution, the
protein concentration is increased causing the protein to precipitate
to form crystals. This technique is very sensitive to the
crystallization parameters: concentration of the constituents of the
solution, pH, and temperature. Growing a successful crystal often
requires experimenting with the crystallization parameters. In any
case, the process of crystallization is especially slow and is often
measured in terms of weeks.
The hanging drop technique has been used in flight in the western
world mainly by two teams. Littke's team 3,4 has carried out many
flights including Spacelab missions (1, D-1 and planned for D-2 and
IML-I) and rocket missions on the TEXUS program. They have carried
out these studies with the proteins lysozyme and beta-galactosidase,
and have observed increased rate of growth and larger crystals when
compared to proteins crystallized on the ground. A U.S. team headed
by Bugg 1,5 has also flown hanging drop experiments on STS-51D, 61C,
51F, and 51F. They used lysozome, human serum, albumin, human
C-reactlve protein, and concanavalin. Both teams have experienced
crystal growth ranging from 22 times (beta-salactosidase) to 1000
times (lysozyme) the volume of those produced on the ground (under the
same conditions).
A study carried out by the Harvard Business School in May 1985
indicated that pharmaceutical firms would be willing to pay between
one and two hundred thousand dollars (U.S.) to have a protein
crystallized in microgravlty. This economic potential is driving
firms in the U.S. (Instrumentation Technology Associates, McDonnell
Douglas) and in Europe (Natra and Intospace) to develop private
protein crystallization hardware. Such systems are aimed at carrying
out their operations in an autonomous, or at least in a semi-
autonomous fashion, aboard spacecraft with their own re-entry
capability.
Bioreactors
The culture of mammalian cells in btoreactors is used in the
biotechnology industry for the production of hormones, enzymes, viral
vaccines, antigens, antibodies, and cells. Because of gravity, the
content of the bioreactor must be mixed in order to obtain a good
distribution of nutrients, oxygen, temperature, and pH. This mixing
creates a harsh hydrodynamic shear environment detrimental to fragile
mammalian cells. If not mixed properly, the cells tend to congregate
and by zone sedimentation fall to the bottom of the bioreactor.
Further, the requirements for oxygenation creates foaming in the
bioreactor which also damages cells. 6 The above factors contribute to
limiting the concentration and density of the bioreactor broth. The
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concentration and density of the solution are directly linked to the
optimal performance of bloreactors; the higher the density, the more
cost effective is the bioreactor run.
In microgravity, zone sedimentation disappears which should reduce
the aggregation of cells. 0nly gentle mixing is required to
distribute the nutrients and oxygen. These factors permit higher
concentrations and densities to be achieved. Additionally, since the
cells do not need to maintain the same surface forces that they
require in higher gravity, they can divert more energy sources for
growth and differentiation 6,7 and hopefully increase products. It is
anticipated that the driver for a space bloreactor will be the clear
need for labile materials to be purified by a subsequent space
process, e.g., electrophoresis. The first space bioreactor was
developed by the Johnson Space Flight Center under the guidance of
Morrlson. 8 In support of these developments of a space bloreactor,
NASA has taken an aggressive stance, funding several university
research teams to study reactor vessel fluid dynamics, shear
conditions, cell stress proteins, and cell metabolism in reactors.
Further, in addition to the current NASA bioreactor, 8a a rotatins
culture vessel (cllnostat)is under development for study as a 1-G
counterpart to the space bioreactor.
Cell PhysioloeY
Work related to the culture of cells in mlcrogravlty has been
carried out on rocket flights as well as on Spacelab 3 and more
recently on Spacelab D-I.9 It is on this last mission that the most
extensive and fascinatlng work was carried out, demonstrating a
significant improvement in the productivity and differentiation
characteristics of a variety of cells. This supports some of the work
carried out by Hymer I0 at the Center for Cell Research at Penn State
University on rat pituitary and by a French-Soviet team on parameciums.
The pattern of increased (altered) cell activity may be a consequence
of microgravity due to the decreased cell interactions (contacts) when
cells are freely, suspended. One set of results from the D1 mission
should raise concerns. The study demonstrated that human lymphocytes
have a negligible response to mltogenlc stimulants in culture.
Further, cells tested from the astronauts exhibited a 50% reduction in
response over the ground base controls. If bacterla/infectlous agents
have enhanced activity and the lymphocyte cells which provide our
immunity are suppressed, we must be concerned about the potential
consequences in the health of space travelers. Future mlcrogravlty
experiments are needed to further define these preliminary
conclusions. These cell studies may indeed lead to an understanding
of the mechanisms by which cells control production of hormones and
other cell products. Wlth this knowledge, control of enhanced,
sustained secretion of product by cells is possible.
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Conclusio_
The United States, along with its research partners, has performed
a variety of space studies related to the growth of cells, production
of cellular products, purification of biologics, and the production of
protein crystals. 11'I2 Future experiments for microgravity need to be
carefully identified and designed to provide maximal return of
information. The desire to consider a space biotechnolo_y research
focus is understandable, since the United States has the research base
for both space and biotechnology areas which are unparalleled in the
world. However, marrying the two areas will require that
practitioners from both disciplines work together to identify the
critical needs and capabilities of each. Most importantly, this
effort will need the strong dircctton of leaders with vision. This
report has been written with these underlying considerations.
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VI. REVIEWS OF BIOTECHNOLOGY INDUSTRY
The survey identified a clear and immediate need--the need for
biotechnologlsts to understand the space program and its environment.
Nevertheless, if the space biotechnology effort is to move forward,
driven by blotechnology industry demands, space engineers and
technologists, in turn, must understand what is required in the
blotechnology fields and respond to those specific needs. Thus,
biotechnologlsts need to describe to NASA the future directions of
their field and the present technologies.
To broaden this report to NASA, biotechnolo&y specialists have
reviewed their fields and identified production limitations in the
agricultural, medical, and veterinary blotechnology areas. The first
report highlights the economic significance of the blotechnology
field. Written by the Arthur Young High Technology Groupj this report
offers insight into the important product areas for blotechnology.
The goal of this series of reports is to educate and stimulate
development of new ideas for research and development, of new
collaborations, and of new applications for the resources of outer
space.
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A. BlotechnoloR7 Business
Mr. John James, Arthur Young High Technology Group
Introduction
The products of blotechnology are moving into the marketplace,
some of them highly publicized, others filling their niches
successfully without fanfare. At different stages in different market
segments, the process has been rougher than expected, but the industry
is learning from each success and temporary barrier.
Progress Towards the Marketplace
Blotechnology products are not yet reachlng the marketplace
routinely, but the experience curve pitched upward in 1987. The rate
of product introduction differs considerably across the various
markets. Some human therapeutics, long under the approval process of
the Food and Drug Administration, have just begun to reach the markets
for which they were intended. Others expected to reach the market In
1988-89 are of the nature of "flagship products," taken by investors
and the general public as symbols of the industry. Their
commercialization is being closely followed and their market
performance will be regarded by some as leading indicators for the
industry as a whole.
Diagnostics are already and will continue to be more plentiful in
the marketplace and should cumulatively make an enormous contribution
to medical progress. However, because diagnostic products support
medical decision-maklng and do not directly work "miracle cures" they
are unlikely to draw the publicity attendin6 certain therapeutics.
The exception to this generalization has been in AIDS diagnostics
which are of urgent interest to the community and a major element in
the blotechnology industry's work on the disease.
Biotechnology applications in agriculture have been less glamorous
and, for the moment, la6 behind. However, it Is belng remedied at
every level--in the universities that train plant and animal
scientists, in industry itself, and in Government, which is
responsible both for regulatory matters and for considerable fundin_
of new research. The slower start says nothing about the prospects
for the future. Biotechnology will have enormous impacts on
agriculture, improvin& crop yields, developing crops for harsh
environments and promoting healthier, more productive herds. World
hunger is a serious challenge; biotechnology is an important part of
the answer.
Unique and Not Wholly Unioue
The biotechnology industry is not unique from start to finish in
its commercialization process, as many people believe. It shares the
obli&ation to submit certain products for regulatory testing with the
pharmaceutical industry and with chemical companies that manufacture
pesticides and herbicides. It also shares with these industries the
possibility of occasional disappointments or delays owing to
regulatory requirements. It shares scientific complexity at the R & D
stage with the pharmaceutical, chemical and electronics industries. It
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shares obligations in manufacturing with the food processing and other
industries. It is perhaps closer to the universities than any other
industry, from which have come many key personnel and product
development programs. However, this university connection is not
unique; for example, the recent flurry of interest in super-
conductivity originated in an industry lab but quickly extended to
university researchers.
All of this said, the biotechnology industry is unique and
rightfully defends its uniqueness. Some of the major biotechnology
companies with a therapeutic focus intend to become vertically
integrated biopharmaceutlcal companies--that unobtrusive prefix
speaking to the continued uniqueness of the enterprise.
Pharmaceutical firms are likely to evrlve into blopharmaceutical firms
in the 1990's. The blotechnology industry may, in effect, acquire the
pharmaceutical industry in technological terms if not financial and
not vice versa, as some analysts have predicted.
Organization for the Long Term
Vertical integration is much in the minds of biotechnology
executives at the present stage of industry development. In business
terms, vertical integration means wholeness, completeness,
independence, maturity and it is, as a consequence, the noble idea of
many biotechnology companies. Their goal is to evolve into fully
integrated companies with R&D, manufacturing, regulatory management,
and marketing and sales functions available in strength, in house.
However, some of us (at Arthur Young) have begun to question this
ideal in its practical application. Certain biotechnology companies
should and will become vertically integrated; others will do well to
take a look at that strategic goal in relation to their real
strengths, current and anticipated.
Vertical integration is not the only route to profitability and a
mature organizational profile. A number of different models are
emerging in the industry, from R&D houses with sound commercial
futures to vertically integrated, fledgling blopharmaceutical firms--
and everything in between. Strategic partnerships with firms that
have complementary strengths are likely to be a permanent part of the
blotechnology industry's commercialization strategy. This does not
necessarily spell second class status for those that choose other
paths; the industry is likely to consist of many different
organizational configurations.
Emerging Issues
Patents, competition, pricing, managing the regulatory process,
product liability insurance, and key people are among the issues that
will increasingly engage the industry attention.
The patent issue may well be paramount at the moment because it
impinges on everything the blotechnology companies do. Patents
contribute to the definition of market niches and can severely narrow
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or close the gateways to those niches. Biotechnology companies that
have targeted the same market niches and have developed reasonably
parallel products, at great cost, may find themselves drawn into a
turf battle at the gateways.
Competition is a fast-emerging issue. The origin of blotechnology
in university research and the continuing connection of blotechnology
companies with research groups in universities and other
not-for-profit institutions has, until recently, helped to disguise
the fact that biotechnology companies are commercial enterprises
approaching a competitive marketplace. In addition, investors have
had confidence in the industry and helped to finance it through public
equity participations and limited partnerships. The return on
investment they now expect can only be won in the competitive arena.
Biotechnology companies will not lose the scientific vision and
business acumen that have sustained them so far, but they will be
increasingly pitted in competition with each other and with major
established companies. Partners are a competitive weapon, but not the
only one. Marketing expertise, manufacturing efficiency, pricing
strategies, and other mainstream business skills will play their part.
Pricing is likely to emerge as an issue when some of the flagship
products reach the marketplace. The advantage of patent protection
allowing a freer hand to recoup high product development costs more
quickly, may be offset to some degree by other factors. Therapeutic
dosages priced at $1,000 or more may be priced down both by
competition or public disfavor.
The regulatory process has recently emerged as a controversial
issue. The natural assumption that a good product will make good
progress through the regulatory process has been shaken not only in
the therapeutic area but in agri-tech as well. Regulatory decision
criteria have shown themselves to be complex and demanding - not
without reason - and the management of the regulatory process has
visibly become an indispensable skill.
Access to highly qualified people has been and remains a necessity
for the industry. Biotechnology has proven its ability to attract
outstanding professionals in science, medicine, and management, but
companies inevitably compete against each other for the same people.
Key people are considered by blotechnology companies to be a leading
competitive advantage. Senior blotechnology officials tend to be a
breed apart with business skills, entrepreneurial spirit, and
scientific knowledge in roughly equal measures. Such men and women
w111 always be a scarce resource.
The abiding issue in the industry is to stay on course - to
maintain a high level of sophisticated R & D to finance product
development creatively and to reach the marketplace with profitable
innovative products in which the industry as a whole can take pride.
The industry has acquired a strong public presence, considerably more
so this year than in the past. If the recent trends continue and the
industry's major stakeholders maintain faith in the promise it holds,
it will remain in the public spotlight for many years to come.
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mo A_ricultural Bio_echnology
H. W. Scheld, Ph.D., Phyto Resource Research, Inc., College
Station, Texas and A. D. Kirkorlan, Ph.D., Dept. of Biochemistry,
University of New York, Stoneybrook
Agricultural biotechnology from the plant science perspective is a
broad, complex field, and there is considerable overlap of technique
and technology into areas properly termed industrial biotechnology and
chemical engineering. It is, moreover, a rapidly moving field. It is
to be expected that by the time this document has been read, there
will be other, new developments.
It is beyond the scope of this overview to enter into a detailed
discussion of the techniques that are used. The purpose here is to
provide a framework that can be used by the nonblo]oglst, technical
manager in thinking about agricultural blotechnology concepts and
approaches in his or her program planning. As a general and arbitrary
but defensible classification, we subdivide agricultural blotechnology
into three major categories: microbial products and techniques, crop
improvement, and plant products or chemicals obtained by non-
traditional methodology. We will highlight the main approaches
representing the state of the art in these areas and provide a few
recent and specific examples of each.
Microbiological Methodology and Products
Microbiological methods are the basis for much of what is known as
genetic engineering and are applied in exploitation of wide variety of
cell systems in chemical engineering and industrial microbiology.
However, there are specific uses to which microbial systems are put
for support of agriculture. The primary emphasis here is upon the
development of crop management approaches which are environmentally
benign in comparison with pesticides, herbicides, fertilizers, and
crop or soil conditioners now in common use.
For perhaps 20 years, a natural bacterial pathogen of insects,
Bacillus thuringiensls, has been used as an insecticide in control of
Lepldopteran insect pests. This method has involved the production of
Bacillus thurinllensls in fermentor-culture and the spray application
of stabilized spore suspensions onto crops. With the advent of
molecular genetics methodology, however, there have been renewed
efforts in radically improving the insecticidal properties of the
Bacilli cells themselves, through the development of advanced
techniques in the screening for improved bacterial strains. EcoEen
Inc., of Langhorne, Pennsylvania, and the US Department of Agriculture
at Beltsvtlle are pioneers in this area. Even more radically, the
plant itself is being rendered less susceptible by insertion of genes
for toxic bacterial protein. Several companies including Monsanto,
Rohm and Haas, and Advanced Genetic Sciences Inc. of Oakland,
California are experimentally producing such transformed plants.
It has long been known that some soils are more beneficial to
crops than other soils. This is related, in part,, to the physical
chemistry of the soil. However, a significant portion of it has been
found to be related to microbial populations. There has been a
significant effort to select or develop and encourage specific
organisms which can enhance productivity. For example, Biotechnlca
International in Cambridge, Massachusetts, is testing genetically
altered Rhlzobium, a symbiotic nitrogen fixing bacterium, for
inoculation into legumes which are the natural hosts of these bacteria.
It is also known that certain bacteria and fungi tend to
antagonize one another; that there is a balance of these organisms in
the soil. Recently there has been an effort in development of
bacterial fungicides and in the selection and genetic englneerln8 of
bacteria which can be introduced into the soil or onto plants to
antagonize certain phytopathogenic fungi. Ecogen, Inc. is producing a
preparation of Pseudomonas (trade name, Daggar G) aimed at control of
dlsease-causlng soil fungi.
A special case which has been very much in the news recently
because of the opposition of environmental groups is the recent
experiments with Frostban by Advanced Genetic Sciences Inc. This
preparation consists of a culture of Pseudomonas svrin_ae which has
been altered by recombinant DNA techniques to remove the gene
responsible for the ice nucleation compounds found in plant leaf
bacteria. These bacteria, when inoculated onto plants, are able to
crowd out the populations of unmodified (ice nucleating) bacteria and
thus impart freezing resistance to the plant leaves.
Crop/Plant Improvement
Efforts in selection or breeding for improvement of crop plants
have been ongoing for thousands of years. Molecular genetic
technology approaches have been built on an already large experience
and genetic base. Despite their relative newness, they have already,
in many cases, produced quite spectacular results even when compared
to the very substantial improvements obtained by more conventional
methods.
Pest resistance has naturally been one objective that has been
pursued with considerable vigor. A number of efforts are being
considered in which molecular genetic techniques are being used to
insert genes into plants; it is hoped that these genes will stimulate
the production of various compounds which will result in increased
resistance to pests. In addition to insertion of the gene for B.
thu_ineiensis toxin, efforts are underway to insert other genes
enhancing plant resistance, such as a gene for toxin tolerance. For
example, the US Department of Agriculture, ARS, in Beltsville,
Maryland, is using protoplast fusion techniques to introduce the genes
for Leptine, an insect repellent compound found in a specific wild
potato, into domestic potato plants in order to provide resistance to
the Colorado potato beetle.
Herbicides are used in production of all of the major crops. No
herbicide is specific for weeds alone, and a significant cultural cost
in modern crop production is associated with the efforts to avoid
herbicide contact with the crop plants as well as with losses due
directly to inadvertent herb contact with the crop. A recent approach
which has been the subject of heavy investment by various chemical
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companies and that is gaining wide attention, is the development of
crop plants which are resistant to the commonly used herbicides. The
most prominent of these are the experiments in Insertion of genes for
resistance to RoundUp (a widely used and extremely efficient
nonselective herbicide) being pursued by Monsanto. Experiments along
the same lines are being conducted by E. I. Dupont for resistance to
sulfonyl urea herbicide.
The improvement of quality or the alteration of particular crop
plant products is of considerable interest, and there have been major
efforts over the years aimed at improvement by conventional methods.
Currently, a number of efforts use molecular genetic techniques to
improve various use qualities of the major food crops. For example,
Biotechnlca Internatlonal is producing alfalfa strains with increased
protein content. The American Soybean Association has begun to
manipulate the oil composition of soybeans. Calgeme Inc., of Davis,
California, has developed the marker genes and techniques for
genetically transforming canola, or oli seed rape, for modification of
oil composition. Sungene Technologies Corp., of Palo Alto,
California, has achieved similar capabilities for producing high oleic
acid sunflower oil for the food frying industry. The efforts in
product improvement are as diverse as the products. For example, DRA
Plant Technology of Cinnamlnson, New Jersey, has developed a new
variety of hlgh-solids tomato to be used specifically in tomato paste
production.
Conventional methods of crop production have served well in the
long search for increased crop productivity. Classical plant
selection and breeding and the improvement of cultivation techniques,
the use of herbicides, growth regulators, and fertilizer application,
and the precise manipulation of water and other stresses have resulted
In very large increases in productivity. There is, however,
considerable interest in utilization of the new technologies for
improving productivity. This takes the form of improvements in
resistance to environmental stresses as well as improvements in the
general reactions which govern productivity. For example, E. I.
Dupont is experimenting with insertion of genes for higher rates of
photosynthesis with the assumption that productivity is gained at a
single point. However, there is a major problem here in that
productivity, as such, is not subject to simple genetic manipulation
in the way that resistance to herbicides and pests or the increases of
quality or quantity of specific products are improved. All of the
processes of productivity are governed by many genetic factors
interacting in extremely complex ways. Thus, we are faced with the
problem of knowing much more about how to change the plant than we
understand about what precisely needs to be changed. There is a clear
need for a systems approach to the improvement of productivity in
plants.
A somewhat different aspect of the plant improvement technology is
in the use of biotechnology as the tool for effectlng the various
transformations desired. Plant tissue culture and cell culture which
derive from the techniques of microbiology are the primary tools.
They are used, not only for the genetic transfer, but in the
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propagation and proliferation of the genetically altered materials.
It is worth noting that the protocol for each plant species or strain
is usually different, and each, at the moment, must be worked out
through trial and error. While reports of somewhat spectacular
successes are constantly appearing, the relative number of plants that
can be transformed is quite small compared to the number needed.
Individual successes should not be taken as indications that large
problems are solved.
The task of merely introducing new DNA into a plant cell still has
no very satisfactory solution. The fact that a plant has a rigid cell
wall has greatly restricted the insertion of genetic material. The
evolving solutions that have been brought to bear on this problem
include preparet_on of plant protoplasts and development of methods
aimed at inducing plant protoplasts to fuse. More positive but
laborious techniques involve the direct injection of foreign DNA
containing the desired genetic material into the plant cells or
protoplasts. The latest approaches include the use of lasers to open
holes in the plant cells in the presence of concentrated DNA solutions
and the use of explosive charges to blast particles containing the DNA
Into and through the plant cells.
The effectiveness of any of these techniques in producing a useful
plant then relies upon the capability for regeneratin_ whole plants
from the single cells (somatic embryogensis) and upon subsequent
testing of these regenerated plants for the presence of the desired
traits. All of this must be laboriously accomplished for each plant
species or strain at a time. Multiplication of such transformed
plants to commercially useful numbers will then rely either upon the
production of seeds or resorting to cell or tissue culture techniques
again to propagate the improved genetic material with concomitant mass
expenditures of energy and labor. Here is a specific major need for
technological improvements in automation in every stage, ranging from
genetic transformation through the multiplication and preparation of
propagation material for field use.
PI_% Products _ Chemicals
For thousands of years, useful chemical products have been
extracted from plants collected from the wild or grown in conventional
agricultural systems. These "secondary products" of plants are still
of great economic importance. Roughly 70% of the drugs,
pharmaceuticals, flavorings, and perfumes are either extracted
directly from plants or processed from plant products. More are
synthesized from models provided by plant chemicals. There are still
a great many potentially useful plant chemicals to be discovered, and
there has been recent growing interest in initiating new concerted
searches for such chemicals.
In spite of our dependence upon natural plant products, many of
these so-called secondary plant products are in very short supply, and
an enormous effort has to be expended to get then_, In some cases
plants are not available because they come from endangered native
habitats in developing countries. In other cases, cartels control
their production and import. In other cases, very large quantities of
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plant materials must be processed to obtain tiny quantities. There is
thus a growing need for development of sources of such chemicals,
sources which are more reliable and which are not subject to limits on
production or on quality. In effect, the need is for transition from
agricultural and wild gathering methodologies to a blotechnology for
optimized, stable manufacture of products which are, in some cases, of
strategic importance. There is a major need for the development of
this technology in terms of biochemical and automated techniques.
This first requires screening for novel plant chemicals and subsequent
production of plant materials in bulk amount in cell culture systems.
Concluding Remarks
This discussion has related primarily to the genetic technology of
plant systems and the manipulation in various ways for the improvement
of the plant and Its products or of the production system. The
discussion has been simplified for the sake of brevity. The reader
should not be led by this to believe that the technology is simple.
There are some cautions that should be given special note. First, it
is generally considered by plant scientists that the plant is
genetically over-bullt compared to animal systems and is likely to be
a much more difficult system to manipulate. A number of very
interesting successes have been seen. Compared to the needs and the
possible range of manipulations, however, these may be considered
relatively superficial. Moreover, none of the advances of the genetic
technologies noted have yet reached full commercial realization for a
number of technical reasons related to the complexities mentioned
above.
One hears the occasional comment by non-blologlcal managers having
minimal or no biological training, that it appears that plant
biologists in general cannot glve them many new ideas about what may
be done wlth plant systems. The plain fact of the matter is that the
new ideas are not easy to come by and wouldn't be recognized unless
they were potentially extremely valuable; any plant scientist who had
such a good idea would naturally be quite reticent about discussing
such things with anyone.
It should be noted, with emphasis, that one of the major
limitations on bringing a great deal of plant biotechnology to the
market place is the lack of availability of conventiQnal engineering
technology rather than of _enetlc engineering technology. Most of the
manipulations required in producing genetic materials and in
processing these plant materials for use In the field are extremely
labor intensive. There is a major need for automation and for
development of mechanical technology for carrying such material
through the various stages and particularly into the mass production
end of the process. This problem has received very little attention,
even in a cursory manner.
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C. Human Biotechnolo_Y
Robb E. Moses, M.D., Cell Biology, Baylor College of Medicine
Introduct_o_
Human biotechnology is entering several new arenas. We can now
determine the presence or absence of disease states, in some
instances, for which we do not have an understanding of the molecular
basis of the disease, instrumentation has allowed improved monitoring
of body functions, and biochemical synthesis allows the development of
targeted drugs.
Current Status
Recombinant DNA--The overwhelming factor in current medical
advances is recombinant DNA methodology. Nowhere is this more clearly
manifest than in the field of human genetics. Cloning, restriction
endonuclease mapping, and sequencing of human genes allows the
diagnosis in some instances of diseases which have remained a riddle
at the biochemical level. One example is the Lesch-Nyhan disease.
This disease is the result of an abnormal purlne metabolism and
produces severe mental retardation, failure to thrive, and
self-mutilatlon. We have an understanding of the biochemical basis
for Lesch-Nyhan disease, but recent accomplishments including clonln8
the gene for this x-llnked disease affords the opportunity for
pre-natal diagnosis. Duschenne Muscular Dystrophy represents a recent
triumph of "reverse genetics." By the isolation and identification of
the gene for this x-llnked muscular dystrophy which is invariably
fatal by the end of the third decade, the protein product, dystrophln,
involved in the disease process has just been isolated. 1 Thus
recombinant DNA technology has allowed for the identification of
individuals who are affected and has led to new understanding at the
biochemical level. While the two diseases mentioned are x-llnked,
cystic fibrosis is an autosomal recessive disease, the most common in
Caucasian populations. The gene itself has not been isolated and
characterized, but very close markers have been isolated allowing
prenatal diagnosis and identification of affected individuals when
adequate family studies are available. Huntington's disease, a severe
central nervous system degenerative disorder with onset in the fourth
decade or even later, is an autosomal dominant disease. We now have
closely linked markers allowlng identification of affected Indlvlduals
for this dlsease. 2 Thus, although we lack an understanding of the
molecular basis of the disease, we are able to make a prenatal
diagnosis.
From the standpoint of therapy, gene replacement will be eagerly
awaited. Presently this is beyond the grasp of medicine, but it is
possible to establish gene transfer in animals creating "transgenlc"
anlmals.
Another area in which recombinant DNA technology promises forward
leaps is that of tumor identification and staging. This is a science
which extends back well over I00 years and which wa_ formerly limited
to surface markers or chromosomal markers in tumors. We are now
beginning to discover the first of what will doubtless be many DNA
markers which are important for prognosis and treatment in individual
tumor types.
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A third arena in which recombinant DNA technology serves modern
medicine is the production of bio-active molecules. This list
includes hormones, drugs, and cellular products. With the human
population increase in the world, it has simply been impossible to
meet demand with natural products. An excellent example of this is
growth hormone which has been cloned and has been released to the
market within the last year. The drive to produce the recombinant
human growth hormone was accelerated because it was found that some of
the natural product was contaminated with a slow virus which gave rise
to neuro- degenerative disorders in individuals who had received the
growth hormone treatment. 3 The recent unlimited availability of
growth hormone will offer clinical relief to individuals who might not
have qualified under the former strict guidelines. Additional
categories of products which are being produced include the
tnterleukins and interferon. These drugs are active in certain
disease processes in improving the quality of life or survival. 5 Thus
the productive capabilities of recombinant DNA technology offer
totally new levels of attack on diseases.
Instrumentation--In the area of instrumentation, much has been
accomplished in the last two decades in miniaturization and
sensitivity. Examples of this are endoscopy procedures and the
development of intrauterine fetoscopy. Although technically
demanding, fetoscopy is nov routinely available in several large U.S.
medical centers. Coupled with other advances in instrumentation such
as improved resolution by the non-invasive imagin_ technique of
ultrasound in real time, the accurate positionin_ of the invasive
procedures has allowed improved safety and comfort for the patient.
At the same time, the development of modern external monitoring
devices for blood pressure and heart rate have given medicine the
opportunity to monitor patients with duration or specificity not
available previously.
In the area of cytogenetlcs, development of seml-automated
scanning for chromosome preparations has achieved a practical
application. This means it is now posslble to avoid such dependence
on skilled labor.
Where is human biotechnolo_v _otne?
Recombinant DNA technology will continue to be a major contributor
to human biotechnology for the foreseeable future. This technology
will require the continued co-development of computer systems to allow
the storing and comparison of nucleic acid sequences in even more
accessible and friendly formats.
Science is committed to sequencing the human genome. This is an
effort which is somewhat comparable in scope to the moon shot effort
of NASA. The estimates for the total sequencing have run in the 10 to
15-year range with a variety of estimates for total cost. 4 While this
is an actively debated current topic, we can anticipate that it is
reasonable for the time needed to be cut by a factor of 3 with the
development of new DNA sequencing techniques and improvement of
collating and storing of data in computers.
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There will be continued improvement in instrumentation. The goals
of instrumentation improvement will be miniaturization and
non-invasiveness. Magnetic resonance imaging, which has just become
available within the last two years, promises to displace the
computerized tomography X-ray approach which has been developed and
brought to such a usefulness over the last i0 year. Magnetic
resonance imaging allows the clinician to obtain information regarding
the functionality of body tissues as well as a static picture to be
interpreted.
Drugs under development will give previously unlmagined control
against the formation of thrombosis and clotting; we will probably see
the first active intervention in cardiovascular accidents (strokes);
there will be third generation drugs for the control of lipid and
cholesterol levels in the individual; there are on the horizon new
cardio-active drugs, and chemotherapy for cancer will enter a new
phase of usefulness within the next 3 to 4 years.
What are the technlca_ roadblocks?
The technical roadblocks which can be identified readily at this
stage include improved software for nucleic acid sequences,
acquisition and retrieval, as well as comparison. Decreased
invaslveness of instrumentation will remain a persistent goal. The
avoidance of pain in testing and treatment will become a primary goal
of medicine over the next decade.
Socio-political roadblocks will increase with regard to
environmental considerations in using animals for testing and using
isotopes in man. An area of development of medicine which will
probably require increased attention over the next two decades will be
the area of the human psyche. In particular, I anticipate that the
management of stress in patients will be a very fruitful area as
medicine becomes more and more mechanized. The patient consequently
has a new type of stress during diagnosis and treatment. In addition,
the application of the new technologies poses major problems for
society: Should candidates for a job be drug-tested? Should
candidates for a Job have polymorphic DNA testing to indicate risk for
diseases which are common in society such as diabetes, heart disease
and stroke? Can an employer refuse to hire an individual on the basis
of such results? Should the recombinant DNA technology be used to
diagnose "silent" diseases in the individual with the incumbent
psychological risk this implies?
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D. Animal Health/Veterinary Medicine
Saul Kit, Ph.D., Biochemical Virology, Baylor College of Medicine
Analysts have estimated that by 1995, 30% of the animal health
market will consist of biotechnology-derived products and services, as
compared with only 4.8% of the total agribusiness market ($2.3 billion
out of $47.9 billion). Currently, over i00 blotechnology companies in
the U.S.A. are engaged in research and development on animal health
projects. This strong emphasis on animal health biotechnology is not
surprising, considering that animals provide humans with food,
clothing, recreation, sport, and power. Animals are also human
companions. Hence, animal health is inextricably connected to human
health. Animals must be healthy to assure our food supply and the
other items listed. On the economic side, outbreaks of animal
diseases may bankrupt farmers and ranchers. Animals and humans are
subject to common diseases, that is, zoonoses such as rabies and
influenza. Therefore, barriers to animal diseases also interrupt or
terminate human epidemics. Finally, research into the natural
diseases of animals provides important parallels and models for
analogous studies on human diseases. Drug experiments which cannot be
performed on humans may be carried out expeditiously on animals. The
results of these studies can then be applied to human therapeutics.
Animal health biotechnology encompasses the diagnosis, treatment,
and prevention of animal disease and the improvement of livestock
productivity. In 1986, there were 120 test kits available for use by
veterinarians and farmers for infectious disease diagnosis, for the
determination of the sex of fetuses, and for facilitating fertility.
Examples of the diagnostic kits are those for livestock diseases such
as bovine brucellosis, bovine leukosis, and bovine diarrhea, and those
for diseases of companion animals such as canine heartworm and feline
leukemia. Most of the diagnostic kits employ monoclonal antibodies to
detect the antigens of the dlsease-causing parasites, bacteria, and
viruses. Monoclonal antibodies have also been used to measure
fertility hormones in blood and milk, for example, in pregnancy
testing in mares. In addition, Y-chromosome DNA probing is being used
in combination with embryo cloning to provide cattle of a pre-selected
sex.
In 1983, Genecol 99, the first veterinary therapeutic, was
introduced in Canada by Molecular Genetics, Inc. The product is a
mouse monoclonal antibody for treatment of diarrhea (scours) caused by
E. coi£ in calves. American Cyanamid is treating cows for bovine
mastltls with a pathogen-specific protein cloned and expressed in
Bacillus hosts. Interferons and interleuklns are other therapeutic
products of biotechnology utilized for animal health.
Prior to the development of recombinant DNA techniques, protein
hormones such as bovine and porcine somatotrophlns could only be
obtained by purification from pituitary glands. They were therefore
only available in small quantities and were very expensive. Now such
compounds are available from recombinant organisms in quantities
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sufficient to treat large animals commercially. For example,
recombinant DNA-derlved somatotrophlns have been used to increase the
growth of pigs, to increase the proportion of lean meat to fat, and to
increase milk yield in dairy cows.
One of the most important future uses of biotechnology in animal
health is that of the production of transgenic animals. The first
model experiment along these lines was carried out by Ralph Brinster,
who produced a transgenic mouse expressing the rat growth hormone
gene. Since that time, transgenic rabbits, sheep, and pigs have been
produced. Super salmon are being engineered in Japan by injecting
cloned salmon growth hormone into the cytoplasm of uncleared
fertilized salmon eggs. Production of transgenic animals opens up the
possibility of introducing extra copies of genes coding for desirable
traits--for example, to improve muscle growth, milk, egg, and fiber
production. Another possibility is the use of transgenic animals as
expression systems for desirable proteins. Simons and co-workers in
Edinburgh, Scotland, have generated transgenic mice carrying the sheep
milk protein, beta lactoglobulin (BLG), and shown that, in such mice,
BLG is specifically and abundantly made in the mammary gland during
lactation. These findings suggest that the manipulation of milk
composition by gene transfer has considerable potential for the
improvement of dairy animals. One may also fantasize transgenic
domestic sheep which produce vicuna or alpaca wool.
Among the most fruitful applications of blotechnology to animal
health are the development of many novel genetically engineered
vaccines. These include subun_t vaccines, modifled-llve virus
vaccines, and live subunlt virus vaccines.
Subunlt vaccines incorporate only a part of the pathogen and are
therefore non-infectlve. This approach was used in a vaccine launched
by Intervet International in April of 1982 to protect calves and pigs
from enteric colibacilosls. Their vaccine, Nobl-vac LT K88, consisted
of copies of genes for adhesion factors inserted into multicopy E.
toll plasmld, thereby allowing for large-scale antigen production.
Modlfled-live virus vaccines consist of replicating viruses with
genetically engineered deletions in virulence factors to enhance their
safety. Unlike conventional llve-virus vaccines, genetically
engineered deletion mutants cannot revert to virulence. The first
recombinant DNA-derived modified-live virus vaccine to be licensed for
manufacture and sale was developed by Vrs. Saul and Malon Kit of the
Baylor College of Medicine and NovaGene, Inc. The U.S.D.A. licensed
0MNIVAC in 1986 after extensive field testa demonstrated that 0MNIVAC
could be used safely in pregnant sows in all stages of gestation and
in newborn piglets to prevent the deadly swine disease called
AuJesky's disease (mad-itch; pseudorabies). In the 0MNIVAC vaccine, a
virulence gene which encodes the enzyme thymidine kinase was
permanently deleted so that there was no danger of the vaccine
accidentally causing central nervous system disease or abortion. More
than a million doses of 0HNIVAC have been used on U,S. farms over the
last 2 years without any complaints from the users. Analogs of
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modified-live virus vaccines for cattle and equine diseases have also
been developed by Drs. Kit. In addition, second generation vaccines
have been produced and licensed. OMNIMARK, for example, consists of
OMNIVAC further modified by the detection of a gene which encodes a
major virus surface protein, called GIII. Pigs infected with field
strains of pseudorables virus always develop antibodies to gIII.
However, pigs vaccinated with 0MNIMARK, which lacks the gene for
gIII, do not develop gIII antibodies and, hence, can be differentiated
from field strain-infected animals by simple blood tests. This
development has opened the possibility for eradicating pseudorabies
disease and is also beneficial to the farmer in that pigs protected by
vaccination can be shipped to other locations. Previously, shipment
of vaccinated pigs was restricted because blood tests were not
available to distinguish vaccinated from infected animals. Vaccinated
animals gave a positive blood test for pseudorabies virus. Hence, the
possibility could not be excluded that the vaccinated animal was
already harboring a latent virulent virus which might endanger a herd.
One of the most important uses of modifled-live virus vaccines is
that of engineering live subunit vaccines. Live subunit vaccines
utilize modlfled-live viruses as vectors to amplify and deliver
subunit immunogens from heterologous microorganisms to the vaccinated
animal. At the present time, the most popular llve subunit vaccine
utilizes Jenner's smallpox vaccine virus, Vacc_n_a, as a vector.
Hybrid Vaccin_a vaccine viruses expressing several different foreign
proteins have been engineered and tested in the laboratory. However,
none has yet been approved for manufacture and sale by the United
States or foreign governments. The first recombinant Vaccin_a vaccine
to undergo open field testing contains the antigens that are required
for protection against rabies. The first field trial of the
Vaccinia-rabies hybrid virus is being managed by the Belgium Fund for
Research Against Rabies in a Joint program with the Wistar Institute
of Philadelphia, PA; Tramsgene, France's blotechnology research and
development firm; and Institute Rhone-Merieux of Lyon, France. In
November of 1987, foxes inhabiting a wooded military reservation in
southern Belgium were vaccinated orally by sowing their territory with
succulent chicken heads containing capsules of the hybrid
Vaccinla-rabies vaccinla. The military enclave was chosen for the
field release test because the area was closed to civilians and
domestic animals and was rich in wildlife, much of it rabid. The
managers of the trial are tracking the fate of their vacclne-seeded
chicken heads, which are marked by tetracycline fluorescent label,
traceable in the bones of animals that take the bait. Preliminary
results indicate that the foxes on this enclave did take the bait.
The Wistar Institute has also requested permission to test the
hybrid Vaccinia-rabies vaccine in wildlife on uninhabited islands off
the coasts of Virginia and the Carolinas.
Vaccinia virus is only one of the many viruses that are being used
as vectors for llve subunlt vaccines. The strategy adapted by
NovaGene, Inc. of Houston, Texas employs the U.S.D.A. approved OMNIVAC
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pseudorables virus as a vector so that swine would be immunized
against Aujeszky's disease and, likewise, a second microbial disease.
Similarly, infectious bovine rhlnotracheltls virus is being used both
to immunize against this important bovine disease and to serve as a
vector for the immunogens of other bovine microbes.
Large scale protein purification and sequencing devices would
greatly facilitate the production of sub-unlt vaccines and of virus
reagents for diagnosis. Yet, the most critical need for small
blotechnology firms is adequate and sustained funding to benefit from
the economies of scale.
The largest of the new blotechnology companies are capitalized at
about 25-50 million dollars. However, most of the new biotechnolo&y
companies have been founded by entrepreneurs with minimal
capitalization. Although these small companies are likely to develop
the most innovative products and to be efficient and cost effective,
they are often on shaky grounds economically. Therefore, the strategy
adopted by many small companies is that of forming alliances with
universities, research institutions, government laboratories (like
NASA), and the grant multinational corporations. The highest priority
must be given by small biotechnology companies to obtain funding to
maintain an essential cadre of trained personnel for a 5- to 10-year
period, at which time their cash flow may increase for essential
capital equipment and facilities for long-term growth and expansion.
Long-term low interest government loans, governmental partnerships
with small companies, or seeding grants represent imaginative ways to
enhance the chances of success of the small biotechnology companies
and to increase local jobs.
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VII. RECOMMENDATIONS FOR FOLL0W-UP
The survey shows that biotechnology companies recognize the value
of research and development. As an industry, they are very much
involved in the process and understand that there is potential value
in space blotechnology research. On the whole, industry executives
are not well informed about the microgravlty environment and the
results of previous space biotechnology studies. A need exists to
provide basic information about the space environment and the past
work in this field.
Some 83% indicated that space based research would be valuable to
the biotechnology industry. Over 50% of the companies indicated that
they would be willing to participate in space biotechnology. Roughly
one third indicated that they would want to participate in workshops
and cooperative research activities with NASA. These statistics
indicate that there is interest in space blotechnology which could
complement NASA's own space blotechnology and human performance needs
in connection with a permanent presence in space.
The results of this industry profile, together with the key
contacts established during the course of this study provide the basis
to develop a U.S. Space Blotechnology Institute (SBI). Such a group
could be patterned after the GEOSAT Working Group which was developed
in the mid 1970's in the earth resources field.
The functions of the Space Biotechnology Institute could include
the following:
io
2Q
o
4o
1
1
.
Develop for NASA a plan for communication with and
development of understanding of the U.S. biotechnology
industry and the university based research programs.
Create and operate a NASA-Industry-Unlverslty worklng/users
group.
Conduct workshops and conferences for information exchange
and develop educational materials for industry.
Develop new simplified mechanisms for NASA/Industry working
agreements, contracts, HOU, JEA, etc.
Establish the requirements for the development of
blotechnology research facilities which could be used in
cooperative ground and space flight research and development.
Identify research opportunities, evaluate research proposals,
and coordinate ongoing research efforts.
Support NASA in the integration of experiments and
applications.
-42-
VIII. APPENDICES
-43-
APPENDIX A
INDUSTRY QUESTIONNAIRE
BACKGROUND INFORMATION FOR SPACE BIOTECHNOLOGY QUESTIONNAIRE
I. Definitions: BIOTECHNOLOGY for the purposes of this study covers
the following areas:
Bioprocessing
Cell/Tissue Culture
Enzymology
Fermentation
Hybridoma/Cell Fusion
Large Scale Purification
Process Monitoring Control
Purification/Separatlon
Recombinant DNA
Sequencing
Synthesis
2. Study Objectives:
A. To determine industry's understanding and expectations about
NASA's plans for conducting biotechnology and space biology
research in the Space Station.
B. To determine industry's perception about NASA activities to
encourage and assist private enterprise in space.
C. Determine what type of information would be useful to blo-
technology corporations to assist them in becoming active
participants in the commercial utilization of space.
n. What is the blotechnology corporate understanding of space
sciences and technology? What is their understanding of the
space environment?
E. What are the sensitivities of biotechnology companies about
entering into collaborative relationships with NASA,
universities, and other biotechnology companies?
F. Are there company funds currently being committed to space
related biotechnology research?
Go What are the key trends and future events which might impact
industry's decision to enter into space related research
activities? What type of ground and flight research is needed
to fulfill critical biotechnology needs to stimulate industrial
participation in the space station program?
FACT SHEET - BACKGROUND INFORMATION
Space-related Biologics% Research
i. Manned space flights for over 25 years.
2. Biological payloads began in the 1960's.
3. Manned skylab experiments (1972-1974): Biological and blotechnology
experiments, including studies on antlgen-antlbodles and cell culture
growth.
4. Space shuttle and space lab studies (from 1981). Focus on bloprocesslng,
llfe sciences, and materials sciences.
Soace Attributes
i. High vacuum (up to 10-14 torts).
2. Infinite heat sink
3. Extreme temperature gradients.
4. Microgravlty
In orbit, the centrifugal force balances the gravitational force so that
the mass of a satellite exists in a state of apparent zero gravity. The
term mlcroEravltY has been coined to suggest the relatively small effect
of gravity which can be obtained in orbit. It has been taught that a
fundamental property of a liquid was that it would conform to the shape of
the vessel which contained it. This is not true in microgravity because
weak forces called surface tension and adhesion become dominant. Liquid
may form a single large drop in the center or it may adhere in a thin
layer over the container's inner surface or in one of many almost random
combinations. Without external body forces the familiar role of
convection (the rising of llghter fluids and their replacement by heavier
ones) is absent. This has real implications in any process involving the
need for a high, uniform temperature. The absence of convection and the
ability to process materials at uniform temperature in a contaminant-free
environment permits the formation of crystals, the size and purity of
which are impossible to create on earth. These mlcrogravlty phenomena
have important implications for the electronics and pharmaceutical
industries. As such, the opportunity to experiment in space is valuable
in the knowledge it might reveal. Once discovered, it may be possible to
reproduce these substances on earth in production quantities.
Recent Space-based Biotechnoloav Research
1. Bioseperations, using electrophoresis, potential use in isolation of rare
cells.
2. Protein crystallization, potential use in pharmaceuticals and electronics.
3. Cell physiology, potential in exploiting cell product synthesis.
Useful Readings
Johnston, R.S. and Dietletn, L.F. (eds.) Biomedical Results from Skylab.
Scientific and Technical Information Office, NASA, Washington, DC, 1977.
Rindone, G.E. (ed.) Materials Processinz in the Reduced Gravity
Environment o_ Svace. Elsevier Science Publ. Co., New York, 1982. Todd,
P. Space Bioprocessin_. Biotechnology _:786-790, 1985.
Biotechnolo_y Study Team
Study Manager: Mr. Richard S. Johnston, Senior Advisor
Center for Space and Advanced Technology
(713) 481-4808
rechnlca_ Advisors: Dr. Baldwin H. Tom, Associate Director,
Bloprocesslng Research Center,
UT Health Science Center at Houston
(713) 792-4433
Dr. David Norton, Director STAR Center
Houston Area Research Center
(713) 363-7922
Advisory Panel: Dr. Bob Stone, Institute of Biosciences and
Technology, Texas A&M
Dr. Robb Moses, Baylor College of Medicine
Mr. Peter G. Ulrich, Biosciences Corporation of Texas
Dr. Saul Kit, Baylor College of Medicine
Mr. A1 Scheld, President, Houston Biotechnology, Inc.
SPACE BIO_OLOGY 0UESTIONNAIRR
The NASA biotechnoloEy program is being developed to provide U.S. corporations a
window in the development of space biotechnology research and new technologies
which can aid progressive companies. Additionally, these programs wlll help U.S.
biotechnology corporations maintain their competitive positions with Japanese and
European firms which are aggressively developing space biotechnology. Opportunities
exist for U.S. corporations to participate in NASA fu_dlng.
I. WHO ARE YOU?
Name:
Title:
Firm:
Address:
Telephone Number: ( )
2. ARE YOU FAMILIAR WlTH NASA's SPACE PROGRAMS?
Some Not
KnowledKeabl_ Knowledge Familiar
a) Space Shuttle [ ] [ ] [ ]
b) Space Station [ ] [ ] [ ]
c) Space Biology and Blotechnology [ ] [ ] [ ]
d) Commercial Programs [ ] [ ] [ ]
I would like more information on the above: a[ ] b[ ] c[ ] d[ ]
3. ARE YOU FAMILIAR WITHTHE SPACE ENVIR01_qENT?
4.
o
o
a) Low gravity (microgravtty)
b) Low pressure (vacuum)
c) Space Radiation
Some Not
Knowledgeable K_0w_ed_e Familiar
[] [] []
[1 [] []
[] [] []
I would llke more information on the above: a[ ] b[ ] c[ ]
DO YOU PERCEIVE VALUE IN SPACE RESEARCH FOR THE BIOTECBNOLOCY INDUSTRY?
Yes No
a) Research in space for space-based processes [ ] [ ]
b) Research in space to understand earth processes [ ] [ ]
c) Commercial biotechnology use of space [ ] [ ]
d) 0verall Space Biotechnology [ ] [ ]
Yes [ ] No [ ]WOULD YOU LIKE TO PARTICIPATE IN SPACE BIOYZO_O_?
If yes, indicate possible interests below:
a) Workshops (space environment, space biotech opportunities, etc. [ ]
b) User group for Space Biotechnology [ ]
c) Cooperative Research Programs with NASA [ ]
d) Cooperative Research Programs with Universities [ ]
e) Other [ ]
IF YOU FEEL THAT YOUR FIRM WOULD BE INTERESTED IN SPACE BIOTECHNOLOCY, PLEASE
FILL IN THE REMAINDER OF THIS QUESTIONNAIRE. OTHERWISE, PLEASE FOLD AND
PLACE IN ENVELOPE PROVIDED AND MAIL TODAY. THANKS FOR YOUR PARTICIPATION.
PART II
in this section we would llke to understand your sensitivities to participation
in Space Biotechnology and to get your ideas on directions NASA might take. The
information acquired will be kept confidential and will not be attributable to
your organization.
7. _/P/Dlrector of Research:
8. VP/Dlrector Corporate Development:
9. Major Corporate Technologies:
i0. Major Products:
ii. Is your company a part of any existing Joint Ventures and/or Consortlums?
Yes [ ] No [ ]
List:
12. Company Resources:
Number of Research Staff Members:
Research Budget: Over $i00 Million [ ]
$I0 to I00 Million [ ]
Under $I0 Million [ ]
% Space Related Blotech
13. Company understanding of U.S. Corporate Programs in Space Commercialization:
Aware Not Awa_e
McDonnell Douglas-Electrophoresls [ ] [ ]
3M Corporatlon-Proteln Crystal Studies [ ] [ ]
Space Industries-Industrlal Space Facility [ ] [ ]
14. Do you envision that the Space Station Program will provide support to the
Blotechnology field? Yes [ ] No [ ]
How?
-2-
i5. Technology Information: What are the most difficult technologies facing the
blotechnology industry? (For example: separation of product, scale up of
production, etc.) List in order of importance.
16. What type of information or scientific data would you suggest is
needed from NASA by Biotechnolosy industries to encourage partici-
pation in space research activities?
17. What are the key trends and future events which may impact the biotechnology
industry's decision to enter into space related activities?
Industry:
Government:
Competition (International):
Other:
18. Could you suggest research areas that NASA should pursue which would be of
benefit to the U.S. Biotechnology Industry?
-3-
19. Would you consider the formation of a joint venture to pursue Biotech research
in space?
Yes [ ] No [3
20. Do you have any other suggestions on how to broaden the US industries parti-
cipation and interest in trying to exploit the uses of the space environment
by the Biotech community?
Yes E] No []
COMMENTS
21. Would you be willing to attend a Spring 1988 Workshop in Houston to review the
findings of this questionnaire and to review Space Biotechnology?
Yes [ ] No [ ]
22. Finally, any other suggestions or comments you might have?
-51- F
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BIOTECHNOLOGY BIBLIOGRAPHY
Current Assessment of Biotechnology
A Bibliography
-- The last major public study on biotechnology was the 1984 OTA study listed
below. Since that study reviewed the status of biotechnology to that point,
most of the references here are to studies between 1984 and 1988.
General
Commercial Biotechnoloav: An International Analysis.
January 1984 SuDoc #Y3.T22/2:C73/7 612 pg.
-- RESEARCH ORGANIZATION: Office of Technology Assessment
PUBLISHER: U.S. Government Printing Office North Capital and H St., NW
Washington DC 20402
_ United States of America
TELEPHONE: (202)275-2051
Assesses competitive position of U.S. with respect to Japan, United
Kingdom, Switzerland, France, and Federal Republic of Germany in commercial
development of new biotechnology. Discusses uses in pharmaceuticals,
agriculture, chemistry, energy production, and bioelectronics. Identifies
U.S. biotechnology companies; and U.S. and foreign companies involved in
joint ventures. Shows distribution of foreign and domestic sales of top 20
U.S. and foreign pharmaceutical companies, 1981; number of new products by
_ country of origin, 1961-1980, 1981, 1982, 1983; and pharmaceutical research
and development expenditures by country, 1964, 1973, 1978.
Biotechnoloqy : status and perspectives
Daniel I.C. Wang
Wang, Daniel I-chyau, 1936-
Corporate Source: American Institute of Chemical Engineers.; Meeting
(1986 : Miami Beach, Fla.)
New York : American Institute of Chemical Engineers, 1988.
Publication Date(s): 1988
ISBN: 0816904375
LC Call No.: TP248.2.W36 1988 Dewey Call No.: 660/.6
EVALUATING THE MA;NTENANC_ AND EFFECTS OF GENETICALLY ENGINEERED
MICROORGANISMS.
SAYLER G S; HARRIS C; PETTIGREW C; PACIA D; BREEN A; SIROTKIN K M
DEP. MICROBIOLOGY AND GRADUATE PROGRAM IN ECOLOGY, UNIV. TENNESSEE,
KNOXVILLE, TENN. 37996.
DEVELOPMENTS IN INDUSTRIAL MICROBIOLOGY, P.135-150, 1987.
Pierce, G. (Ed.). Developments in Industrial Microbiology, Vol. 27;
Symposia of the Forty-second General Meeting of the Society for Industrial
Microbiology, Boston, Massachusetts, USA, Aug. 4-9, 1985.
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x+183p.+++Elsevier Science Publishers: Amsterdam, Netherlands (dist. in the _
USA and Canada by Elsevier Science Publishing Co. Inc.: New York, New York,
USA). Illus. ISBN 0-444-80870-1
Language: ENGLISH
A CRITICAL EVALUATION OF MICROBIAL PRODUCT FORMATION IN BIOLOGICAL
PROCESSES.
RITTMANN B E; BAE W; NAMKUNG E; LU C-J
DEP. CIVIL ENGINEERING, UNIV. ILL. URBANA-CHAMPAIGN, URBANA, ILL.
61801,U.S.A.
WATER SCIENCE AND TECHNOLOGY, VOL. 19, NO.3-4, P.517-528, 1987.
Thirteenth Biennial Conference of the International Association on Water
Pollution Research and Control, Part 2, Rio de Janeiro, Brazil, August
17-22, 1986. WATER SCI TECHNOL
Language: ENGLISH
PB87-141362/XAB
Competition an_ the Role of Technology: An Assessmen_ of the
Biotechnoloav/Aaribusiness Industry
Sakura, D. ; Wheat, D. ; Berkley, P. ; Reardon, M. ; Bondaryk, R. Industrial I
Research Inst., Inc., New York.
Corp. Source Codes: 044789000
Sponsor: Little (Arthur D.), Inc., Cambridge, MA.; Economic Development ._
Administration, Washington, DC.
Apr 85 163p
See also PB87-141396. Prepared in cooperation with Little (Arthur D.),
Inc., Cambridge, MA. Sponsored by Economic Development Administration,
Washington, DC.
Languages: English
NTIS Prices: PC A08 Journal Announcement: GRAI8706
Country of Publication: United States
Contract No.: EDA-RED-803-G-83-5; EDA-99-7-13611
The objective of the study was to identify technology development areas in_
the agribusiness industry which would maintain or increase the
international competitive position of the United States. Biotechnology was
emphasized since this new developing technology offered the greatest _
potential for technical areas benefiting from accelerated development. The
study covers animal health products and nutritional ingredients, animal and
plant breeding including the seed industry, and agricultural chemicals
including fertilizers and pesticides. The study concluded that the United --
States is the technical leader with few exceptions, though European and
Japanese researchers are rapidly developing increased capability in this
important field. Progress is currently limited by the lack of basic -
scientific information; yet the major effort world-wide on biotechnology
makes it certain scientific breakthroughs will occur within the next decade
that will greatly change the agribusiness industry.
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PB86-247095/XAB
Biotechnology: Analysis of F%de_a_ly Funded Research
General Accounting Office, Washington, DC. Resources Community and
Economic Development Div.
Corp. Source Codes: 010682026
Report No.: GAO/RCED-86-187; B-223522
Aug 86 41p Languages: English
NTIS Prices: PC A03/MF A01 Journal Announcement: GRAI8626
Country of Publication: United States
In August 1984 and again in April 1985, ii federal agencies were surveyed
about the nature of all biotechnology-related research they support. The
report contains biotechnology research activity profiles for five of the
agencies: the Department of Agriculture (USDA), the Environmental
Protection Agency (EPA), the Food and Drug Administration (FDA), the
National Institutes of Health (NIH), and the National Science Foundation
(NSF). Each profile includes estimates of the fiscal year 1985 level of
support, in terms of dollars obligated and number of projects funded, for
agencywide activity for the conduct of research and development,
biotechnology-related research, and biotechnology risk assessment research.
The data for these estimates were compiled by contacting officials in
agency budget offices and agency program offices, and from written
responses surveys.
g7-26356-5 2
New Developments in BiotechnQlogy: Background Papers {Biotecholoqy
legal, ethical, and economic issues, series)
Office of Technology Assessment
GPO; for individual bibliographic data, see below
ITEM NO: 1070-M
Y3.T22/2:2B52/4/v. (nos.)
DOC TYPE: SERIES PUBLICATION
JOURNAL ANNOUNCEMENT: 8711
Series of reports on legal, ethical, and economic issues surrounding new
developments in biotechnology.
Reports are described below in order of receipt.
85-2046-11.5
Biotechnology ( Biotechnoloqy industry [us) intl competitiveness_ with
selected operating data and listing of col_aborative agreements, 19705-83
and projected to 2000)
<July 1984. 217 p. C61.2:T22/6. LC 84-603710. MC 85-4201. S/N
003-009-00430-6. $7.00. ASI/MF/5>
Includes 19 tables showing:
a. Projections: world demand for biotechnology products by category: and
projected sales of laboratory equipment by type; with some actual data.
b. Collaborative agreements: lists showing terms of research, marketing,
and other agreements between individual Japanese and non-Japanese f_m.s,
small and large U.S. firms, U.S. firms and universities, and U.S. and
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foreign firms.
c. R&D and patents: NIH and NSF R&D funding , by research area; and
patents, by date granted, country, and owner (U.S. and foreign
corporations, governments, and individuals).
d. Industry operations: share of shipments from top 4 and top 8 firms, by
product; and foreign investment in U.S. firms, by investor and recipient.
Data are for 1970s-83, with projections to 2000.
86-26113-200
Biotechnoloav: The U.S. DeDartment of A_riculture's Biotechnoloqy --
Research Efforts (Biotechnolocrv R&D Droiects of USDA. fundinq by State,
environmental releases, and risk assessment. 1985 GAO rD_)
General Accounting Office
Oct. 1985 80 p. +
FICHE: 3 ITEM NO: 546-D
GAI.13:RCED-86-39BR REPORT NO: GAO/RCED-86-39 BR
DOC TYPE: SPECIAL SERIES
JOURNAL ANNOUNCEMENT: 8603
Report on biotechnology R&D projects conducted or sponsored by the USDA
Agricultural Research Service (ARS), Office of Grants and Program Systems _
(OGPS), and Cooperative State Research Service (CSRS), FY84-85.
Data are from ARS research compendium; OGPS records; and a survey of
State agricultural experiment stations and veterinary medicine colleges,
funded by CSRS in F¥84 and conducted by GAO and the National Assn of State -
Universities and Land Grant Colleges.
Survey covered biotechnology research projects, staff, expenditures by
funding source (USDA, other Federal and State agencies, and industry), and
funding needs; use of genetic engineering methods; expected environmental
releases of genetically engineered organisms, and potential release
problems and response efforts; and research risk assessment activities.
Includes text statistics and 8 tables showing number of USDA-funded
biotechnology research projects, and USDA biotechnology and total
agricultural research funding, by USDA funding agency; ARS planned
biotechnology research expenditures, by research topic and region; and -
summary survey results; often by State.
Also includes facsimile survey form with tabulated responses; and lists
of State agricultural experiment stations and veterinary colleges, with
descriptions of biotechnology research accomplishments and projects
expected to result in release of genetically engineered organisms, all
arranged by State.
Special: Dio_echnik.
SDecial Report on BioteGhnglo_.
Wirtschaftswoche
June 21, 1985 no.26 pg.82-94
PUBLISHER: Gesellschaft fur Wirtschaftspublizistik G W P mbH and Company KG -
Kasernenstrasse 67 P.O.B. 3734 Dusseldorf D-4000
West Germany
TELEPHONE: (OII49521)559-0;TELEPHONE: (01149211)8388-0 TELEX: 932934 dehla
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tELEX: 8582917
Consists of various articles dealing with markets for biotechnology
products in the USA, Japan, and the FRG and profits and profits
-- expectations of industries engaged in research on biotechnology and
production or use of biotechnology products. Special reference is given to
competition on national and international markets and competition for the
introduction of new products and the exploitation of new research results
in the field of biotechnology for food processing, bioelectronics,
agriculture, energy, and chemical and pharmaceutical industries. Articles
are supported by tables showing forecasts of dates for the industrial use
of biotechnology research results in the USA (1985-2015) in different
industries, government funding for research on biotechnology in the FRG
(1974-85), estimates of the size of the world market for biotechnology
products (1980-2000) by industry.
BIOT_CHNOLOGY INDUSTRY
- FEB 1987 26 P. $250 ONE-TIME
Publ: Research From Wall St, New York, NY 212-645-4500
Availability: PUBLISHER
Report No.: Q787
Document Type: MARKET/INDUSTRY STUDY
The two-part report focuses on new drug developments and industrywide
-- competition. Part One offers highlights of the November 1986 annual
American Heart Association meeting: potential use of Genentech's t-PA for
unstable angina; Centocor's cardiac imaging products and antiplatelet
monoclonal antibody; SOD use; and Eli-Lilly's t-PA product. Part Two
-- profiles Amgen, Genentech, Centocor and Applied biosystems. Tables contrast
industrywide therapeutic and animal health care/supply and diagnostic
products and competition.
STATUS OF BIOTECHNOLOGy
JUL 1987 270 P. $995 ONE-TIME
Publ: Market Intelligence Research Co, Mountain View, CA 415-961-9000
Availability: PUBLISHER
Report No.: A231
-- Document Type: MARKET/INDUSTRY STUDY
Biotechnology in this report has been defined to include primarily the
use of recombinant DNA, monoclonal antibodies, and advanced somatic cell
_ techniques in the production of new pharmaceuticals, diagnostics, and
agricultural products. Features of the study include a discussion of how
the application of the new biotechnologies has affected the investment
_ community, an overview of the science behind the new biotechnologies, major
near-term applications, and a discussion of the theoretical potential for
growth and development of the markets for each of the applications
discussed.
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88-9626-6.20
BiotecbDoloav Research and Development Activities in Industry: 1984 and
1985 ( _iotechnoloqy R&D _undinq by industry by fundinq source, and_
emDlo_rment, by field. 1984-85)
<May 1987. v+27 p. NSF 87-311.. NSI.22:B52/984-85. ITEM 834-T. ASI/MF/3>
Report on industrial biotechnology R&D spending and S/E employment,
1984-Jan. 1986. Based on a survey of 94 firms, representing approximately --
56% of biotechnology R&D spending in 1985.
Includes i chart and I0 tables showing industrial biotechnology R&D
spending, by source of funds and major application and technique, 1984-85;
and S/E employment, by field and major technique, as of Jan. 1985-86.
Cell/tissue culture
87-26356-5.1
Ownership o_ Human Tissues and Cells Ownership o_ Human Tissues and
Cells. New Developments in Biotechnoloav New Developments in Biotechnoloqy:
Ownership of Human Tissues and Cells (Biotechnoloqv products sales and
Drofits. by selected firm. 1985)
<Mar. 1987. vii+f67 p. OTA-BA-337.. CIS Index (87) J952-14.
Y3.T22/2:2B52/4/v.1. LC 87-619804. MC 87-10434. S/N 052-003-01060-7. 7.50. --
ASI/MF/4>
Report on economic, legal, and ethical rights of human sources of tissues
and cells, and rights of physicians or researchers who obtain and develop
these biological materials. Focuses on technologies related to tissue and
cell cultures, hybrid cell lines, and recombinant DNA.
Includes 3 charts and i0 tables showing sales and profits of selected
biotechnology companies, 1985.
Enzymology
ENZYME TECHNOLOGY FOR THE LIPIDS INDUSTRY: AN ENGINeERiNG OVERVIEW.
YAMANE T
LAB. BIOREACTION ENG., DEP. FOOD SCI. TECHNOL., SCH. AGRIC., NAGOYA U_41V.,
NAGOYA 464, JPN.
JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, VOL. 64, NO.12, P.1657-1662,
1987.
Language: ENGLISH
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Fermentation
BIOENGINEERING ANALYSIS AND EVALUATION OF A CONTINUOUS FERMENTATION
PROCESS.
RYCHTERA M; BURIANEC Z; NEDBAL F
INST. CHEMICAL TECHNOLOGY, PRAGUE.
FOLIA MICROBIOLOGICA, VOL. 29, NO.5, P.397, 1984.
16th Annual Congress of the Czechoslovak Society for Microbiology, Banska
Bystrica, Czechoslovakia, Oct. 21-23, 1983. FOLIA MICROBIOL
Language: ENGLISH
A SURVEY OF SEPARATION SYSTEMS FOR FERMENTATION ETHANO_ RECOVERY. SERRA A;
-- POCH M; SOLA C
UNITAT D'ENGINYERIA QUIMICA, DEP. DE QUIMICA, UNIV. AUTONOMA DE BARCELONA,
BELLATERRA, SPAIN.
PROCESS BIOCHEMISTRY, VOL. 22, NO.5, P.154-158, 1987.
Language: ENGLISH
Hybridoma/cell fusion
CELL CULTURE B_OT_CHNOLOGy: EQUIPMENT REAGENTS AND CONSUMABLES
JAN 1986 300 P. $2250 ONE-TIME
Publ: Frost & Sullivan Inc, New York, NY 212-233-1080
-- Availability: PUBLISHER
Report No.: E771
Document Type: MARKET/INDUSTRY STUDY
-- 1983+4 base years, 1985-90 forecasts: CO2 incubators, ultra-low
temperature freezers, biohazard and laminar flow cabinets, cell analyzers
(2 types), mass cell culture systems (6 products), consumables (3 groups, 7
_ components), and reagents (3 groups, 5 products) 1984-90 in each of 6 major
EEC countries and rest of Europe. Market size and shares by product, by
country, by manufacturer. New opportunities in this venture capital
dominated development.
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_rge-scale purification
P_rt_t$on of ce_l partiqles and macromolecules : seDarat_on and
purification of biomolecules, cell oraanelles, membranes, and cells in
aqueous polymer two-phase systems and their use in biochemical analysis and
biotechnoloq7
Albertsson, Per Ake.
3rd ed. New York : Wiley, c1986. 346 p. : ill. ; 24 cm.
Publication Date(s): 1986
ISBN: 0471828203 :
LC Call No.: QH324.9.S4A423 1986 Dewey Call No.: 574.1/92/028
B_otechnoloqy: SeDarations Technoloqv - The Production Hurdle.
November 1984 no. F528 22 pg. PRICE: $300.00
PUBLISHER: FIND / SVP, Research from Wall Street 500 Fifth Ave. New York NY
i0110
United States of America
TELEPHONE: (800)223-2054;TELEPHONE: (212)354-2424
ATT: Van Velsor, Patty
Reports on the U.S. biotechnology market for separations technology
equipment and disposables, 1984-1987. Examines new products, end uses, and
manufacturers.
SEPARATION AND PURIFICATION EOUIPMENT MARKET IN U.S. BIOTECHNOLOGY
APPLICATIONS
SEP 1986 241 P. $1900 ONE-TIME
Publ: Frost & Sullivan Inc, New York, NY 212-233-1080
Availability: PUBLISHER
Report No.: A1661
Document Type: MARKET/INDUSTRY STUDY
Covers forecasts through 1990 by five major market segments
(pharmaceuticals, veterinary drugs, specialty chemicals, agricultural
chemicals, foods and beverages) for filtration: ultrafitration (hollow
fiber, plate and frame, spiral wound), microfiltration, reverse osmosis,
traditional (filter press, rotary drum); chromatography: HPLC, ion
exchange, gel filtration, affinity; centrifuges; disc, laboratory, solid
bowl, tubular; electrophoresis; electrodialysis; cell disruption:
homogenizers, bead mills. Provides 39 company profiles.
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_ ?rocess monitoring control
Mass spectrometry in biotechnoloqical process analysis and control
-- edited by Elmar Heinzle and Matthias Reuss
Heinzle, Elmar.; Reuss, Matthias.
Corporate Source: Institut fur Umweltforschung.; International Federation of
-- Automatic Control.; International Federation of Automatic Control.;
Technical Committee on Applications.
New York : Plenum Press, c1987, xi, 241 p. : ill. ; 26 cm.
Publication Date(s): 1987
ISBN: 030642777X
LC Call No.: TP248.25.M38M37 1987 NLM Call No.: QC 454.M3 M41435 1986
Dewey Call No.: 660/.6
PROCESS INFORMATION AND CONTROL SYSTEMS: A TECHNOLOGY OVERVIEW.
FADUM O
FADUM ENTERPRISES INC., P.O. BOX 368, NORWOOD, MASS. 02062.
TAPPI (TECHNICAL ASSOCIATION OF THE PULP AND PAPER INDUSTRY) JOURNAL,
VOL.70, NO.3, P.62-66, 1987. Language: ENGLISH
Environmental
-- Applications
Assessment and Overview o_ Biotechnoloqy Process
(Final rept. Sep 83-Jun 84)
Stein, N. P. ; Hayes, B. J. ; Gates, N. S. ; Page, G. U.
_ Radian Corp., Austin, TX.
Corp. Source Codes: 029117000
Sponsor: Industrial Environmental Research Lab., Research Triangle Park, NC.
Report No.: EPA-600/7-84-081
-- Aug 84 125p
Languages: English
NTIS Prices: PC A06/MF A01 Journal Announcement: GRAI8421
Country of Publication: United States
Contract No.: EPA-68-02-3171
The report is an overview of industrial biotechnology processes, waste
_ streams associated with these processes, and the effectiveness of current
control technologies in treating process waste streams. (Biotechnology is
defined here as processes that employ microbial cultures or enzymes to
produce a product or effect a specific physical or chemical change.)
-- Commercial applications are divided into contained product manufacturing
processes (industrial fermentation) and uncontained/semicontained processes
(metal extraction, energy production, and pollution control). Agricultural
-- applications of biotechnology, the use of higher order organisms, and
biological treatment of wastewaters are not considered in detail in this
report. Acceptable levels of control for viable microorganisms are
-- currently not well defined. Data on the effectiveness of technologies for
control of viable microorganisms and certain chemical constituents of
bioprocess wastes were found to be very limited.
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Biotechnoloav InstrumentatiQn in 1985
October 1985 150 pg. PRICE: $795.00
PUBLISHER: Theta Technology Corporation 462 Ridge Rd. Wethersfield CT 06109
United States of America
TELEPHONE: (203)563-9400
Examines the following biotechnology instruments: DNA synthesizers,
UV/VIS spectrophometers, gel electrophoresis, robotics, HPLC columns, HPLC
detectors, HPLC systems, computer-aided biotechnology, protein synthesizers
and fermenters. Provides data for current market shares, projected shares
for the next five years, funding for research, trends in instrument design
and usage, and profiles of 32 companies involved in biotechnology research,
1985.
Recombinant DNA
THE USE OF RECOMBINANT DNA TECHNOLOGy IN DNA REPAIR STUDIES IN ESCHERICHIA
COLI: A REVIEW.
SEDGWICK S G
GENETICS DIVISION, NATIONAL INSTITUTE MEDICAL RESEARCH, MILL HILL, LONDON
NW7 IAA.
HEREDITY, VOL. 53, NO.3, P.574, 1984.
200th Meeting of the Genetical Society held jointly with the United Kingdom
Environmental Mutagenesis Society, Liverpool, England, Apr. 2-4, 1984.
HEREDITY
Language : ENGLISH
Sequencing
TECHNOLOGY EVALUATION OF SEOUENCING BATCH REACTORS.
ARORA M L; BARTH E F; UMPHRES M B
JAMES M. MONTGOMERY CONSULTING ENGINEERS INC., 250 NORTH MADISON AVE.,
PASADENA, CALIF. 91109-7009.
JOURNAL WATER POLLUTION CONTROL FEDERATION, VOL. 57, NO.8, P.867-875, 1985.
Language: ENGLISH
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Unclassifed - Chemicals
BIOT_CHNOLOGY IN THE MANUFACTURE OF SPECIALTY AND COMMODITY CHEMICALS:
TECHNOLOGY AND OPPORTUNITIES IN WESTERN EUROPE
MAR 1987 348 P. $3500 ONE-TIME
Publ: Business Communications Co, Inc, Norwalk, CT 203-853-4266
Availability: PUBLISHER
Report No.: 2H-I05
Document Type: MARKET/INDUSTRY STUDY
This study assesses the impact of biotechnology on the manufacture of
specialty and commodity chemicals into the 21st century. Special notice is
taken of recent and anticipated advances in genetic engineering, fermenter
design, biocatalysis, plant tissue cultue and related technologies deemed
likely to make fermentation chemicals more cost competitive with
established chemical synthetic routes. Projections are made for the
chemical products under review, and the commercial prospects for Western
European chemical and biotechnology companies are highlighted.
BIOTECHNOLOGY APPLICATIONS IN CHEM;CALS
NOV 1984 108 P. $1800 ONE-TIME
Publ: Predicasts Inc, Commack, NY 516-462-5454
Availability: PUBLISHER
Report No.: 3532
Document Type: MARKET/INDUSTRY STUDY
This detailed technoeconomic study analyzes the impact of biotechnology
of over 25 chemical products within the aliphatic organic (organic acids,
alcohols and other aliphatics) amino acids, and enzyme segments. Current
and potential applications for the fermentation process are also reviewed
along with an assessment of diffusion for each individual case provided
within a detailed analytical framework of analysis. A review of current
company involvement is also provided.
84-9886-4.78
International Developments in Biotechnoloqy and Their Possible _mpact on
Certain Sectors of the U.S. Chemical Industry International Developments
in BiotechnolQqy and Their Possible Impact on Certain Sectors of the _'.S.
Chemical Industry: Report on _nvestiqation No. 332-174 Under Section 332(b)
of the Tariff Act of 1930
(Biotechnology firms, patents, and trade by country, and effect of
industry growth on US drug and chemical trade, selected years 1979-2000)
<Oct. 1984. xxi+164 p. USITC Pub. 1589. ITCI.12:332-174. ASI/MF/4>
Report on the biotechnology industry, focusing on the potential impact of
industry growth on trade in selected drugs and chemicals, selected years
1979-83 with some projections to 2000. Drugs and chemicals covered are
antibiotics, biologicals, hormones, vitamins, amino acids, enzymes, ethyl
and methyl alcohol, fertilizers, and pesticides.
Includes text statistics and i00 tables showing biotechnology firms;
Space Business Research Center
wBiotechnology Overview May 1988
patents
culture);
country,
to 2000.
held, by class (enzymes, mutation and genetic engineering, tissue --
and imports and exports of each drug and chemical; all by
selected years 1979-83 with U.S. consumption and trade projected
International Developments in Biotechnoloqv and Their Possible Impact on
Certain Sectors o_ the U.S. Chemical _ndustr7: Report on Investiqation
No.332-174 Under Section 332(bj of the Tariff Act of 1930.
Michels, David G.; Briggs, Tedford C.; Greenblatt, Jack
October 1984 USITC Pub.1589 Irregularly 185 pg. PRICE: $Free
PUBLISHER: U.S. International Trade Commission 701 E. St., NW Washington DC
20436
United States of America
TELEPHONE: (202)523-0173
Reports on international developments in biotechnology and their
possible effect on the U.S. chemical industry. Tables, compiled from U.N.,
U.L., and foreign government and industry sources, indicate number of
projects and government funding, product lines, licenses, and patents,
1979-1982; domestic production and shipments, exports, imports, and percent
of ratios, 1979-1983; and capital expenditures, cost of operations, and raw
materials costs, 1983.
Advances in Biop;ocess Technoloqy: _ndustrial / Specialty Chemicals via
Bioloaical Sou_ges / Rou_es.
1985 PRICE: $700.00
PUBLISHER: Technical Insights, Inc. P.O. Box 1304, 158 Linwood Plaza Ft.
Lee NJ 07024
United States of America
TELEPHONE: (212)233-1080;TELEPHONE: (201)944-6204
Analyzes the market for bioprocessing and biological raw materials,
1985. Examines research and development and new technology. Provides
addresses and telephone numbers of leading research groups and companies.
Space Business Research Center
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Unclassified - Pharmaceuticals
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APPENDIX C
MAILING LIST OF COMPANIES
3r. Norman J. Wald, Manager
Technology Assessment and Acquisition
Abbott Laboratories
ID-gRK/AP6C/Routes 137 & 43
Abbptt Park, IL 60064 Dr. Wald
3_2-937-0201
VP/Research Director
Abcor, Inc.
850 Main Street
Wilmington, MA 01887 Sir or Madam
Ms. Debra Coyman, Marketing Director
Advanced Genetic Sciences
6701 San Pablo Avenue
Oakland, CA 94608 Ms. Coyman
415-547-2395
Dr. Dennis E. Vaccaro, VP-Marketing
Advanced Magnetics, Inc.
61Mooney Street
Cambridge, HA 02138 Dr. Vaccaro
617-497-2070
Mr. Allen J. Dines
Director Business Development
Agracetus
8520 University Green
Middletown, WI 53562 Mr. Dines
608-836-7300
Or. Philip L. McMahon
Director of R&D
Agritech Systems, Inc.
IO0 Fore Street
Portland, ME O4101 Mr. Shaw
207-?74-4334
Mr. Allan L. Goldstein, Research Director
Alpha l Biomedicals, Inc.
777 14th Street N.W., Suite 410
Washington, DC 20009 Mr. Goldstein
202-628-9898
Dr. Jack Lief, Director Business Development
Alpha Therapeutic Corporation
5555 Valley Blvd.
Los Angeles, CA 90032 Dr. Lief
Dr. Alejandro Zaffaroni, Chairman/CEO
ALZA Corp.
PO Box I0950
Palo Alto, CA 94303-0802 Dr. Zaffaroni
415-494-5222
VPIResearch Director
American Biodesign, Inc.
44 Mechanic Street
Newton, MA 02164 Sir or Madam
Hr. Robert Runckel, Marketing Director
American Biomaterials Corp.
I05 Morgan Drive
Plainsboro, NJ 08536 Mr. Runckel
800-222-3001
Dr. Robert Dugan
Director Corporate Development
American Cyanimid Co.
One Cyanamid Place
Wayne, NJ 07470 Or. Dugan
Dr. Richard L. Eichholz
Manager Strategic Planning
Amersham Corp.
2636 S. Clearbrook Drive
Arlington Heights, IL 60005 Mr. Dunbar
312-5g3-6300 x 255
Dr. W. Neal Burnette, Research Scientist
Amgen
1892 Oak Terrace Lane
Newbury Park, CA 91320 Dr. Burnette
805-499-5725 x 3015
Dr. P. Schratter, Marketing Director
A_icon Division
24 Cherry Hill Drive
Danvers, MA 01923 Dr. Schratter
617-777-3622
VPlResearch Director
Angenics
lOO Inman Street
Cambridge, MA 02139 Sir or Madam
Dr. Dennis Panicali
VP Product Development
Applied Biotechnology
80 Rogers Street
Cambridge, MA 02142 Dr. Panicali
617-492-7289
VPIResearch Director
Applied Biotechnology
80 Rogers Street
Cambridge, MA 02139 Sir or Madam
Dr. Kenneth E. Blackman, Research Director
Applied DNA Systems Inc.
1450 Broadway
New York, NY 10018 Dr. 81ackman
212-302-7000
VPIResearch Director
Applied Protein Technologies, Inc.
I03 Brookline Street
Cambridge, MA 02139 Sir or Madam
617-868-6085
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Marketing Director
BASF Corporation
lO0 Cherry Hill Road
Parsippany, NO 07054 Sir or Madam
201-263-3000
Laura J. Crane
Director, R&D-Laboratory Products
J.T. Baker Inc.
222 Red School Lane
Phillipsburg, NJ 08865 Ms. Crane
201-859-2151 x 9417
Dr. Mark Myslinski
Planning and Business Development
Baxter Healthcare Corporation
1430 Waukegan Road
McGrant Park, IL 60085 Dr. Myslinski
Mr. Louis T. Rosso, President/CEO
Beckman Instruments, Inc.
2500 Harbor Blvd.
Fullerton, CA 92634 Mr. Rosso
714-871-4848
Mr. Deither J. Recktenwald, Senior Scientist
Becton Dickinson Immunocytometry Systems
2375 Garcia Avenue (PO Box 7375)
Mountain View, CA 94043 Mr. Recktenwald
415-968-7744
VP/Research Director
Becton Dickinson & Co.
Corporate Research Center
PO Box 12016
Research Triangle Park, NC 27709 Dear Sir or Madam
Andrew P. Lesniak, Ph.D., Product Manager
Bellco Biotechnology
340 Edrudo Road (PO Bow B)
Vineland, NJ 08360 Dr. Lesniak
800-257-7043
Or. Wayne Patterson, Marketing Director
BiD Engineering International, Inc.
25 Science Park
New Haven, CT 06511 Dr. Patterson
203-786-5055
VP/Research Director
BiD Response, Inc.
550 Ridgefield Road
Wilton, CT 06987 Sir or Madam
VP/Research Director
Biogen, Inc.
241Binney Street
Cambridge, MA 02142 Sir or Madam
Dr. Richard Flavell, Research Oirector
Biogen N.Y.
14 Cambridge Center
Cambridge, MA 02142 Dr. Flavell
Mr. John P. Richard, Marketing Director
Biogenex Laboratories
6549 Sierra Lane
Dublin, CA 94568 Mr. Richard
Joanne T. Caha, Director/Personnel & Amin.
Biomatrix, Inc.
65 Railroad Avenue (P. O. Box 174)
Ridgefield, NJ 07657 Ms. Caha
201-945-9550
Dr. Robert L. Pardue, Research Director
Biosciences Corp. of Texas
4900 Fannin Street
Houston, TX 77004 Dr. Pardue
VP/Research Director
Biotech Research Laboratories, Inc.
1600 East Bude Drive
Rockville, MD 20850 Sir or Madam
Dr. Keith C. Backman
Biotechnica International, Inc.
85 Bolton Street
Cambridge, MA 02140 Dr. Backman
617-864-0040
Dr. Juergen Schrenk, Research Director
Boehringer Mannheim Biochemicals
PO Box 50816
Indianapolis, IN 46250 Dr. Schrenk
800-428-5433
VP/Research Director
Bristol-Myers Co.
Industrial Division
PO Box 657
Syracuse, NY 13201 Sir or Madam
Mr. John Callahan, Marketing Director
Calgene, Inc.
1920 Fifth Street
Davis, CA 95616 Mr. Callahan
916-753-6313
Mr. Robert Tidwell, Marketing Director
California Biotechnology, Inc.
2450 Bayshore Parkway
Mountain View, CA 94043 Mr. Tidwell
415-966-1550
Dr. John Lifter, Director
Viral Immunology
Cambridge Bioscience Corp.
365 Plantation Street
Worcester, MA 01605 Dr. Lifter
617-797-5777
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YPlResearch Director
Cellorgan International, Inc.
300 Park Avenue
_ew York, NY ]OOlO Sir or Madam
Dr. Lawrence Papsidero, Research Director
Cellular Products, Inc.
668 Main Stret
Buffalo, NY 14202 Dr. Papsidero
716-842-6270
Mr. James E. Rurka, Marketing Director
Cetus Corp.
1400 53rd Street
Emeryville, CA 94608 Mr. Rurka
415-420-3300
Mr. John H. Wheeler, VP for Sales and Marketing
Charles River Biotechnical Services, Inc.
251Ballardvale Street
Wilmington, MA 01887 Mr. Wheeler
617-658-6000
Or. Pablo Valenzuela, VP R&D
Chiron Corporation
4560 Horton Street, Suite 0214
Emeryville, CA 94608 Dr. Valenzuela
415-655-8730
VP/Research Director
Ciba-Geigy
444 Saw Mill River Road
Ardsley, NY 10502 Sir or Madam
Dr. William 3. DeLorbe, Research Director
Cistron Biotechnology, Inc.
Box 2004
Pine Brook, NJ 07058 Dr. DeLorbe
201-575-1700
Or. Orrie M. Friedman, Chairman/CEO
Collaborative Research, Inc.
Two Oak Park
Bedford, MA 01730 Dr, Friedman
617-275-0004
VP/Research Director
Collaborative Genetics, Inc.
128 Spring Street
Lexington, MA 01273 Sir or Madam
VP/Research Director
Collagen, Inc.
2455 Faber Place
Bald Alto, CA 94303 Sir or Madam
VP/Research Director
Creative Biomolecules, Inc.
35 South Street
Hopkinton, MA 01748 Sir or Madam
617-435-9001
VP/Research Director
Cutter Laboratories, Inc.
PO Box 8817
Emeryville, CA 94662 Sir or Madam
Dr. Thomas McKearn
Cytogen Corporation
201 College Road, East
Princeton Forrestal Center
Princeton, N3 08540 Dr. McKearn
609-987-8200
Mr. W. Robert Ballantyne, Research Director
Cytogen Corp.
600 College Road E.
Princeton Forrestal Center
Princeton, NJ 08540 Mr. Ballantyne
VPIResearch Director
DNAX Corp.
1454 Page Mill Road
Palo Alto, CA 94304 Sir or Madam
VP/Research Director
Damon Biotech, Inc.
115 Fourth Avenue
Needham Heights, MA 02194 Sir or Madam
VP/Research Director
Diagnostic Technology, Inc.
240 Vanderbilt Motor Parkway
Mauppauge, NY I1788 Sir or Madam
C. F. Thompson, Director of Biotechnology
Dow Chemical Co.
1701 Building
Midland, MI 48674 Mr. Thompson
517-636-1066
Or. J. R. Wolfe, Biotechnology Director
DuPont Medical Products Department
Barley Mill Plaza
Wilmington, DE 19898 Dr. Wolfe
800-551-2121
VP/Research Director
E. I. du Pont de Nemours & Co.
Central Research and Development Dept.
1007 Market Street
Wilmington, DE 198g8 Sir or Madam
Robert L. Taber, President
EG&G Mason Research Institute
57 Union Street
Worcester, MA 01608 Mr. Taber
617-791-0931
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Mr. P. R. Grisdale, Director
Exploratory Sciences Division/Life Sciences
Eastman Kodak Co.
Igog Lake Avenue
Rochester, NY 14617 Mr. Grisdale
716-722-0190
VP/Research Director
Electro Nucleonics Laboratories, Inc.
12050 Tech Road
Silver Spring, MD 20904 Sir or Madam
Dr. Mark P. Becker
Senior Biochemical Engineer
Eli Lilly and Co.
Lilly Corporate Center, KY409
Indianapolis, IN 46285 Mr. Step
317-276-7665
Mr. Phillip J. Servidori, Marketing Director
VP/Research Director
EnBio, Inc.
Union Avenue, #408A
Fairfield, CA 94533 Sir or Madam
Mr. Roy A. Dempsey, CEO and Scientific Director
Endogen, Inc.
451D Street
Boston, MA 02210 Mr. Dempsey
617-439-3250
VP/Research Director
Engenics, Inc.
2 Palo Alto Square, Suite 500
Palo Alto, CA 94304 Sir or Madam
VPIResearch Director
Enzo Biochem, Inc.
325 Hudson Street
New York, NY I0013 Sir or Madam
Mr. Paul Mansfield, Marketing Director
Epitope, Inc.
13425 S.W. Koll Parkway
Beaverton, OR 97006 Mr. Mansfield
503-641-6115
VP/Research Director
FMC Corporation
2000 Market Street
Philadelphia, PA 19103 Sir or Madam
Mr. David Hurwitz, Marketing Director
Fisher Scientific
711 Forge Avenue
Pittsburgh, PA 15219 Mr. Hurwitz
412-562-8300
Dr. Petty Lever-Fischer, Research Director
Flow Laboratories, Inc.
7655 Old Springhouse Road
McLean, VA 22102 Dr. Lever-Fischer
?03-893-5925
Mr. James M. Gower, Marketing Director
Genetech, Inc.
460 Point San Bruno Blvd.
South San Francisco, CA 94080 Mr. Gower
Dr. Phillip Berman
Genetech, Inc.
460 Point San Bruno Blvd.
South San Francisco, CA 94080 Dr. Berman
415-266-1000
VP/Research Director
Genetic Replication Technologies, Inc.
1533 Monrovia Avenue
Newport Beach, CA 92663 Sir or Madam
VP/Research Director
Genetic Systems Corp.
3005 First Avenue
Seattle, WA 98121 Sir or Madam
VP/Research Director
Genetics Diagnostics Corp.
160 Community Drive
Great Neck, NY 11021 Sir or Madam
516-487-4711
Barbara Deptula/Robert Kay Ph.D.
Genetics Institute
87 Cambridge Park Drive
Cambridge, MA 02114 Mr. Kay & Ms. Deptula
617-B76-1170
VP/Research Director
Genetics International, Inc.
50 Milk Street, 15th Floor
Boston, MA 02109 Sir or Madam
Mr. Barry A. Soloman
vP Biomedical Research
W. R. Grace & Co.
25 Hortwe11 Avenue
Lexington, MA 02173 Mr. Solomon
617-861-9600 x 126
Dr. Craig McMullen, CEO
Hana Biologics, Inc.
626 Bancroft Way
Berkeley, CA 94710 Dr. McMullen
Mr. Ben Walthall, Oirecto'r Technical Adman
Hana Biologics, Inc.
850 Marina Village Parkway
Alameda, CA 94501 Mr. Walthall
415-748-3000 ORIGINAL P._GE ,'.'3
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_r. Paul Kamitsuka. Marketing Director
Hazleton Research Products
13804 W 107th Street
Lenexa, KS 62215 Mr. Kamitsuka
913-469-5580
Mr. Richard H. Stevenson
Asst. Director-Exploratory Research
Hoffmann-La Roche, Inc.
340 Kingsland Street
Nutley, NJ 07110 Mr. Stevenson
201-235-4920
Dr. Cam L. Garner, Marketing Director
Hybritech Inc.
PO Box 269006
San Diego, CA 92126 Dr. Garner
519-455-6700
Mr. Steve Murdock, Marketing Director
Hyclone Laboratories Inc.
1725 S State Hwy 89-91
Logan, UT 84321 Mr. Murdock
801-753-4584
VP/Research Director
Hytech Biomedical, Inc.
1440 Fourth Street
Berkeley, CA 94710 Sir or Madam
VP/Research Director
IGI Biotechnology, Inc.
9110 Red Branch Road
Columbia, MD 21045 Sir or Madam
Dr. Huei-Hsiung Yang
Director Research & Engineering
Igene Biotechnology, Inc.
9110 Red Branch Road
Columbia, MD 21045 Dr. Yang
301-997-2599
Dr. Frank E. Ruch, Jr.
V.P. Research & Development
Immucell Corp.
966 Riverside Street
Portland, ME 04103 Dr. Ruch
207-797-8386
VP/Research Director
Immulok, Inc.
lOl9 Mark Avenue
Carpinteria, CA 93013 Sir or Madam
VP/Research Director
Immunew Corp.
51 University Building, Suite 600
Seattle, WA 98101 Sir or Madam
206-587-0430
Mr. H. Stewart Parker, Marketing Director
Immunex Corp.
51 University Street
Seattle, WA 98101 Mr. Parker
VP/Research Director
Immuno Modulators Laboratories, Inc.
10511 Corporate Drive
Stafford, TX 77477 Sir or Madam
Dr. Art Gottlieb, President
Imreg, Inc.
PO Box 56643
New Orleans, LA 70156 Dr. Gottlieb
504-523-2875
VP/Research Director
Interferon Sciences, Inc.
738 Jersey Avenue
New Brunswick, NJ 08g01 Sir or Madam
201-240-3250
VP/Research Director
Integrated Genetics, Inc.
51 New York Avenue
Framingham, MA 01701 Sir or Madam
617-875-1336
VP/Research Director
International Genetic Engineering, Inc.
(INGENE)
1701 Colorado Avenue
Santa Monica, CA 90404 Sir or Madam
Mr. Stanley C. Erck, Marketing Director
Integrated Genetics, Inc.
31 New York Avenue
Framingham, MA 01701 Mr. Erck
Mr. Gary L. Snable, Marketing Director
Invitron Corp.
4649 Le Bourget Drive
St. Louis, MO 63134 Mr. Snable
314-426-5000
Mr. William B. laconelli, Marketing Director
Ionics, Inc.
65 Grove Street
Watertown, MA 02172 Mr. laconelli
617-926-2500
VP/Research Director
Lederle Laboratories
One Cyanamid Plaza
Wayne, N3 07470 Sir or Madam
Mr. James A. Lee, Marketi'ng Director
Life Sciences, Inc.
1818 Market Street
Philadelphia, PA 19103 Mr. Lee
215-299-8700
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Dr. Robert M. Cohn, Research Director
The Liposome Co., Inc.
l Research Way
Princeton Forrestal Center
Princeton, NJ 08540 Dr. Cohn
609-452-7060
VPIResearch Director
The Liposome Co., Inc.
1 Research Way
Princeton Forrestal Center
Princeton, NJ 08540 Sir or Madam
VP/Research Director
Litton Bionetics
5516 Nicholson Lane
Kensington, MD 20895 Sir or Madam
VP/Research Director
Molecular Diagnostics
400 Morgan Lane
West Haven, CT 06516 Sir or Madam
203-934-9229
Dr. David Reed, Research Director
Molecular Genetics, Inc.
I0320 Bren Road, East
Minnetonka, MN 55343 Dr. Reed
612-935-7335
VP/Research Director
Monoclonal Antibodies, Inc.
2319 Charleston Road
Mountain View, CA 94043 Sir or Madam
415-960-1320
Dr. Leon R. Lyle
Associate Director, Medical Products R&D
Mallinckrodt, Inc.
625 McDonnell Blvd. (PO Box 5840)
St. Louis, MO 63134 Dr. Lyle
314-895-2352
Dr. Ernest G. Jaworski
Director of Biological Sciences
Monsanto Company
700 Chesterfield Village Parkway
St. Louis, MO 63198 Dr. Jaworski
314-537-682g
VP/Research Director
Meloy Laboratories, Inc.
6715 Electronic Drive
Springfield, VA 22151 Sir or Madam
Dr. 3ackie Leszczak, Marketing Director
Memtek Corp.
28 Cook Street
Billerica, MA 01821 Dr. Leszczak
617-667-2828
Mr. Tom Defosse, Research Director
New Brunswick Scientific
44 Talmadge Road
Edison, N_ 088]8 Mr. Defosse
201-287-1200
VP/Research Director
New England Biolabs
32 Tozer Road
Beverly, MA 01915 Sir or Madam
617-927-5054
Stanley J. Fidelman, Senior V.P./Planning & Development
Merck Sharp & Oohme Research Laboratories
Division of MERCK & Co., Inc.
PO Box 2000
Rahway, N3 07065 Dr. Fidelman
201-574-5328
Dr. Ronald W. Ellis, Director & Head
Cellular and Molecular Biology
Merck Sharp & Oohme Research Laboratories
West Point, PA 19486
215-661-7545
VP/Research Director
Miles Laboratories, Inc.
I127 Myrtle Street
Elkhart, IN 46515 Sir or Madam
815-g37-8270
Or. Ken Widder, Chairman & CEO
Molecular Biosystems, Inc.
I0030 Barnes Canyon Road
San Diego, CA 92121 Dr. Widden
619-452-06BI
VP/Research Director
Nuclear and Genetic Technology, Inc.
172 Brook Avenue
Deer Park, NY 11729 Sir or Madam
VP Research Director
Novo Laboratories, Inc.
5g Danbury Road
Wilton, CT 06897 Sir or Madam
Dr. Shiu-Lok Hu
Laboratory Director
Oncogen
3005 First Avenue
Seattle, WA 8g121 Dr. Hu
206-728-4800
VP/Research Director
Oncogene Sciences Inc.
Nassau Hospital Professional Building
Suite 330
222 Station Plaza North
Mineola, NY I1501 Sir or Madam
OR,_a._._;_L
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Mr. W. Barry McDonald, Marketing Director
,Sncogene Science, Inc.
350 Community Drive
Manhasset, NY 11030 Mr. McDonald
516-365-g300
VPIResearch Director
Organon, Inc.
375 Mt. Pleasant Avenue
West Orange, NO 11501 Sir or Madam
Mr. Seth Rudwick, V. P. Product Development
Ortho Biotech
Route 202 (PO Box 300)
Raritan, NJ 0886g Mr. Rudwick
201-218-7192
Mr. Michael Burgett, Director
Operations and Development
Ortho Diagnostic Systems, Inc.
I125 Mark Avenue
Carpinteria, CA 93013 Mr. Burgett
805-684-8717
Dr. Jim Gardner
Director of Corporate Strategic Planning
Pfizer, Inc.
235 East 42nd Street
New York, NY I0017 Dr. Gardner
-- 212-573-3267
Dr. Robert M. Flora, VP-R&D
Pharmacia LKB Biotechnology, Inc.
800 Centennial Avenue
Piscataway, NJ 08854 Dr. Flora
201-457-8000
Dr. Stephen M. Courts
VP Therapeutic Research
Quidel
I1077 North Torrey Pines Rd.
La 3olla, CA g2037 Dr. Coutts
61g-450-1533
Mr. E. Michael Egan, Marketing Director
Repligen Corp.
One Kendall Square, Building 700
Cambridge, MA 0213g Mr. Egan
617-225-6000
Dr. Jon A. RudBach
V. P. Research & Development
Ribi Immunochem Research, Inc.
PO Box 140g
Hamilton, MT 59840 Dr. RudBach
406-363-6214
VP/Research Director
Ribi Immunochem Research, Inc.
PO Box 140g
Hamilton, MT 59840 Sir or Madam
VPlResearch Director
Sandoz, Inc.
Route No. lO
East Hanover, NO 07936 Sir or Madam
201-386-7500
Or. Joseph F. Lameudolce
Director of Pharmaceutical Research
Schering-Plough Corporation
2000 Galloping Hill Road
Kenilworth, NO 07033 Dr. Lamendolce
VP/Research Oirector
G. D. Searle & Co
PO Bow I045
Skokie, IL 60076 Sir or Madam
VP/Research Director
Serono Laboratories, Inc.
280 Pond Street
Randolph, MA 02368 Sir or Madam
Or. Ron Wolfe, Research Director
Sigma Chemical Co.
PO Box 14508
St. Louis, MO 63178 Dr. Wolfe
314-771-5765
Mr. John J. Dingerdissen
Scientific Coordinator/Biotechnology Research
Smith Kline & French Laboratories
PO Box 153g
King of Prussia, PA Ig406-og3g Mr. Dingerdissen
215-270-7358
Dr. George Poste, Director of Research
SmithKline Beckman
PO Box 7g2g
Philadelphia, PA Igl01 Dr. Poste
215-751-4000
Dr. Peter Sears
SmithKline Beckman
PO Box 7g29
Philadelphia, PA IglOl Dr. Sears
215-751-4000
Dr. Edgar Haber, President
The Squibb Institute for Medical Research
PO Box 4000
Princeton, N3 08540-4000 Dr. Haber
60g-g21-4487
VP/Research Director
Standard Oil Co. of California
225 Bush Street
San Francisco, CA g4104 Sir or Madam
A. K. Rao, Director of Technology,
Business Development
Stearns Catalytic Division,
United Engineers & Constructors
30 South 17th Street
Philadelphia, Pennsylvania 19101 Mr. Rao
215-422-4210
Ms. Patricia Pallares
Technical Services Director
Summa Medical Corp.
4272 Balloon Park Road, N.E.
Albuquerque, NM 87109 Sir or Madam
505-345-88gi
VPIResearch Director
Syncor International
12847 Arroyo Street
Sylmar, CA g1342 Sir or Madam
Dr. Claire T. Wake, Director
Technical Development
Synergen, Inc.
1885 33rd Street
Boulder, CO 80301 Dr. Hirsh
303-938-6270
Dr. Tony Allison
Syntex Research
c/o Syntex Corp.
3401Hillview Avenue
Palo Alto, CA g4304 Dr. Allison
Dr. Arlen Nordhagen, Director,
Business Development
Synthetech, Inc.
2585 Central Avenue
Boulder, CO 80301 Dr. Nordhagen
303-444-g597
Dr. Thomas Gutshall
Syva Co.
go0 Arastradero Road
Palo Alto, CA 94303 Dr. Gutshall
VP/Research Director
3M
3M Center
St. Paul, MN 55144 Sir or Madam
Mr. Oran W. Nicks
Director, Space Research Center
Texas A&M University
College Station, TX 77843-3118 Oran
40g-845-5293
Mr. David L. Corbet, Marketing Director
T Cell Sciences, Inc.
840 Memorial Drive
Cambridge, MA 02139 Mr. Corbet
617-864-2160
VP/Research Director
Techniclone International Corp.
3301 South Harbor Blvd., Suite I04
Santa Ana, CA 92704 Sir or Madam
Terry Malone, Business Development Manager
Triton Biosciences Inc.
1501 Harbor Bay Parkway
Almeda, CA 94501 Mr. Malone
415-76g-5370
VP/Research Director
Unigene Laboratories, Inc.
110 Little Falls Road
Fairfield, NJ 07006 Sir or Madam
201-882-0860
Mr. A. K. Rao
Director of Technology
United Engineers & Constructors
30 S. 17th Street
Philadelphia, PA 19101 Mr. Rao
215-422-4210
Dr. Curtis Miller
The UpJohn Company
7000 Portage Road
Kalamazoo, MI 49001 Dr. Miller
Mr. Barry Godowsky, Marketing Director
Ventrex Laboratories, Inc.
217 Read Street
Portland, ME 04104 Mr. Godowsky
207-773-7231
Dr. David Berry
Welcomme Research Laboratories
3030 Cornwallis Road
Research Triangle Park, NC 2770g Dr. Berry
VP/Research Director
Worne Biotechnology, Inc.
Medford Medical 8uilsing
Stokes Road, Box 458
Medford, N3 08055 Sir or Madam
609-654-5065
Mr. James 8urchall, Head
Microbiology Division
Burroughs Wellcome Co.
3030 Cornwallis Road
Research Triangle Park, NC Mr. Burchall
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Mr. _tevem C. Mendell, _arket_g _irector
Xoma Corp.
2910 Seventh Street
3erkeley, CA 94710 Mr. Mendell
415-644-1170
Melanie Call, Market Analyst
Zymogenetics
_225 Roosevelt Way NE
Seattle, WA 98105 Ms. Call
206-547-8080
VPIResearch Director
Research and Development Laboratories
One River Road
Schenectady, NY 12345 Sir or Madam
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APPENDIX D
SURVEYED BIOTECHNOLOGY COMPANY PROFILES
Dr. Dennis E. Vaccaro, VP-Marketing
AdvancedMagnetics, Inc.
61 MooneyStreet
Cambridge, MA 02138Dr. Vaccaro_
617-497-2070
TECHNOLOGIES:
MAJORPRODUCTS: Purification (lab-scale)BioMagmagnetic affinity chromatography reagents,
research RIA kits for prostaglandins, thromboxane,
leukotrienes, cyclic nucleotides.
Mr. Allen J. Dines
Director Business Development
Agracetus
8520 University Green
Middletown, WI 53562 Mr. Dines
608-836-7300
TECHNOLOGIES:
MAJOR PRODUCTS:
PRODUCTS UNDER
DEVELOPMENT:
Recombinant DNA, Fermentation, and Cell/tissue
culture
Genetically improved crops, animal health products,
microbial crop treatments.
Rhizoblum, insect resistance crops, disease
resistant crops, vaccine-adjuvants, corn yield
enhancer microbe, vaccines, IL-2 as shipping fever
preventative..
Dr. Philip L. McMahon
Director of R&D
Agritech Systems, Inc.
I00 Fore Street
Portland, ME 04101 Mr. Shaw_
207-774-4334
TECHNOLOGIES:
MAJOR PRODUCTS:
Recombinant DNA, Hybridoma/cell fusion, and
Cell/tissue culture
Diagnostics for animal and food applications
Dr. Richard L. Eichholz
Manager Strategic Planning
Amersham Corp.
2636 S. Clearbrook Drive
Arlington Heights, IL 60005 Mr. Dunbar_
312-593-6300 x 255
TECHNOLOGIES: Recombinant DNA, Purification (lab-scale),
Hybridoma/cell fusion Synthesis, Sequencing, and
Enzymology
Amersham Corp. (continued)
MAJOR PRODUCTS: P-32/S-35 nucleotides: cDNA synthesis and cloning
kits; 1-125; RAS image analysis system; biomedical
research assays; sulpher-35 methionine for protein
synthesis studies; sulpher-35 labelled nucleotides
for sequencing nucleic acids; labelled lymphokines,
growth factors and petides for new drug studies;
monoclonal antibody detection systems.
Dr. W. Neal Burnette, Research Scientist
Amgen
1892 Oak Terrace Lane
Newbury Park, CA 91320 Dr. Burnette_
805-499-5725 x 3015
TECHNOLOGIES:
MAJOR PRODUCTS:
Recombinant DNA L, Fermentation, Purification
(lab-scale), Hybrldoma/cell fusion, Cell/tissue
culture, Large-scale purification, Synthesis,
Sequencing, Enzymology
Erythropolet_n, granulocyte colony stimulating
factor (G-CSF); consensus interferon, gamma
interferon; interleukln-2; hepatitis B vaccine;
porcine and bovine somatotropin; epidermal growth
factor, platlet derived growth factor IGF-I, FGF,
indigo; enzymes; vitamins.
Laura J. Crane
Director, R&D-Laboratory Products
J.T. Baker Inc.
222 Red School Lane
Philllpsburg, NJ 08865 Ms. Crane_
201-859-2151 x 9417
TECHNOLOGIES:
M_JOR PRODUCTS:
PRODUCTS UNDER
DEVELOPMENT:
Purification (lab-scale), Large-scale purification
Chromatography media for protein, chlral and small
molecule separation; high purity solvents for
chromatography, DNA and protein synthesis, solid
phase extraction columns for sample preparation;
TLC plates; buffer salts; electrophoresis
chemicals; dyes, salts and solvents for
bioprocessing.
New chromatography media high purity chemicals and
solvents.
Mr. Deither J. Recktenwald, Senior Scientist
Becton Dickinson ImmunocytometrySystems
2375 Gareia Avenue (PO Box 7375)
Mountain View, CA 94043Mr. Recktenwald_
415-968-7744
TECHNOLOGIES:
MAJORPRODUCTS:
Hybridoma/cell fusion, Cell/tissue culture
FACScan,FACStar, FACStar Plus, Leu monoclonal
reagents, Simultest reagents, CASImageAnalysis
System (flow cytometers, image analysis, monoclonal
antibodies for cellular immunology).
AndrewP. Lesniak, Ph.D., Product Manager
Bellco Biotechnology
340 Edrudo Road (P0 Box B)
Vineland, NJ 08360 Dr. Lesniak_
800-257-7043
TECHNOLOGIES:
MAJOR PRODUCTS:
Recombinant DNA, Fermentation, Hybridoma/cell
fusion, Cell/tissue culture
Cell culture labware and equipment; bloreactor
system utilizing immobilized cells.
Joanne T. Caha, Director/Personnel & Amin.
Biomatrix, Inc.
65 Railroad Avenue (P. O. Box 174)
Ridgefleld, NJ 07657 Ms. Caha_
201-945-9550
TECHNOLOGIES:
MAJOR PRODUCTS:
PRODUCTS UNDER
DEVELOPMENT:
Purification (lab-scale), Bioprocess,Cell/tissue
culture
8iomatrix, Hyladern, BioCare, HA-Z4
Advanced biological matrices with applications in
orthopedics including arthroscopic surgery,
opthalmology, wound care, cardiovascular surgery
and drug delivery.
Dr. Keith C. Backman
Blotechnica International, Inc.
85 Bolton Street
Cambridge, MA 02140 Dr. Backman_
617-864-0040
TECHNOLOGIES:
MAJOR PRODUCTS:
PRODUCTS UNDER
DEVELOPMENT:
Recomblnand DNA, Fermentation, Purification
(lab-scale), Bioprocess, Cell/tissue culture,
Process Monitoring Control, Synthesis, Enzymology
DM/) test for periodontitis, Endo H, chitinase,
silage inoculants, improved rhizobial strains.
Vaccines and therapeutic proteins, amino acids and
vitamins, DNA probes, dental diagnostics and
advanced dental products, crop agriculture,
industrial yeasts, specialty enzymes.
Dr. John Lifter, Director
Viral Immunology
Cambridge Bioscience Corp.
365 Plantation Street
Worcester, MA 01605 Dr. Lifter_
617-797-5777
TECHNOLOGIES:
MAJORPRODUCTS:
PRODUCTSUNDER
DEVELOPMENT:
RecombinantDNA, Fermentation, Purification
(lab-scale), Bioprocess, Hybridoma/cell fusion,
Large-scale purification, Synthesis, Sequencing
Rotaclone rotavirus diagnostic, Adenoclone
adenovirus diagnostic, Clin Ease Leukotest feline
leukemia diagnostic, Recombigen AIDS diagnostic.
Feline leukemia vaccine, AIDS vaccine, infectious
disease diagnostic.
Mr. John H. Wheeler, VP for Sales and Marketing
Charles River Blotechnical Services, Inc.
251 Ballardvale Street
Wilmington, MA 01887 Mr. Wheeler_
617-658-6000
TECHNOLOGIES:
MAJOR PRODUCTS:
Purification (lab-scale), Bioprocess, Cell/tissue
culture, Large-scale purification, Process
Monitoring Control
Optlcell cell culture systems; Maxltap ascites
production system.
Dr. Pablo Valenzuela, VP R&D
Chlron Corporation
4560 Horton Street, Suite 0214
Emeryville, CA 94608 Dr. Valenzuela_
415-655-8730
TECHNOLOGIES:
MAJOR PRODUCTS:
PRODUCTS UNDER
DEVELOPMENT:
Recombinant DNA, Fermentation, Purification
(lab-scale), Hybridoma/cell fusion, Cell/tissue
culture, Large-scale purification, Sequencing
Hepatitis B vaccine, Recomblvax RIBA 216 AIDS
Diagnostic test
Vaccines; AIDS, herpes, malaria, FeLV, CMV;
superoxide dismutase, epidermal growth factor,
IFGs, FGFs, factor VIII, hepatitis and AIDS
diagnostics.
C. F. Thompson,Director of Biotechnology
DowChemical Co.
1701 Building
Midland, MI 48674 Mr. Thompson
517-636-1066
TECHNOLOGIES:
MAJORPRODUCTS:
RecombinantDNA,Fermentation, Purification
(lab-scale), Hybridoma/cell fusion, Cell/Tissue
Culture, Synthesis, Enzymology, Bioprocess,
Large-scale purification, Process Monitoring
Control,
_EN Research Products, Sorvall centrifuges,
Coupler peptide synthesizer, Coder DNA
synthesizer, Zorbax HPLCcolumns, cell culture
products, Genesis 2000 DNAsequencer, AIDS
research products.
Mr. P. R. Grisdale, Director
Exploratory Sciences Division/Life Sciences
Eastman Kodak Co.
1909 Lake Avenue
Rochester, NY 14617 Mr. Grisdale_
716-722-0190
TECHNOLOGIES:
MAJOR PRODUCTS:
PRODUCTS UNDER
DEVELOPMENT:
Recombinant DNA, Fermentation, Purification
(lab-scale), Bloprocess, Hybridoma/cell fusion,
Cell/tissue culture, Large-scale purification,
Process Monitoring Control, Synthesis, Sequencing,
Enzymology
Snomax snow inducer; diagnostic enzymes; blood and
body fluid analyzers.
Pharmaceuticals, pharmaceutical intermediates, food
additives, food additives, fluid analyzers.
Dr. Hark P. Becker
Senior Biochemical En&ineer
Eli Lilly and Co.
Lilly Corporate Center, KY409
Indianapolis, IN 46285 Mr. Step_
317-276-7665
TECHNOLOGIES:
MAJOR PRODUCTS:
PRODUCTS UNDER
DEVELOPMENT:
Recombinant DNA, Fermentation, Purification (lab
scale), Bioprocess, Hybridoma/cell fusion,
Large-scale purification, Synthesis, Sequencing
Ceclor, Humulln, Dobutrex, Darvon Keflex, Oncovin.
t-PA, APC, proinsulin, BST.
Mr. Roy A. Dempsey,CEO and Scientific Director
Endogen, Inc.
451 D Street
Boston, MA 02210 Mr. Dempsey_
617-439-3250
TECHNOLOGIES:
MAJOR PRODUCTS:
PRODUCTS UNDER
DEVELOPMENT:
Recombinant DNA, Fermentation, Purification
(lab-scale), Bioprocess, Hybridomalcell fusion,
Cell/tissue culture, Large-scale purification,
Process Monitoring Control
Ultrapure IL-I, consensus IL-I, anti-TNF alpha,
anti-lymphotoxin (TNF-beta), anti IL-I, anti IL-2,
affinity purified, tumor necrosis factor/cachectin,
interleukln-2, anti-IFN-gamma
Purified human lymphotoxln, antl-hlL-4, LIF,
anti-LIF, anti-GM-CSF
Barbara Deptula/Robert Kay Ph.D.
Genetics Institute
87 Cambridge Park Drive
Cambridge, MA 02114 Mr. Kay & Ms. Deptula
617-876-1170
TECHNOLOGIES:
PRODUCTS UNDER
DEVELOPMENT:
Recombinant DNA, Purification (lab-scale),
Large-scale purification, Sequencing, Enzymology
M-CSF, IL-3, 2d generation TPA, bone growth factors.
Dr. Huei-Hsiung Yang
Director Research & Engineering
Igene Biotechnology, Inc.
9110 Red Branch Road
Columbia, MD 21045 Dr. Yang_
301-997-2599
TECHNOLOGIES:
MAJOR PRODUCTS:
Fermentation, Purification (lab-scale), Bioprocess,
Large-scale purification, Enzymology
Macroin milk/eggwhlte replacer, MinraLac calcium
and milk minerals food supplement; ClandoSan
nematlcide-soil conditioners; butyric and propionic
acids and esters for flavors and fragrances;
LevaSan (Poly-LevyLan ) polyfructose biogum;
streptoccal lysins for clinical diagnostic tests
Dr. Frank E. Ruth, Jr.
V.P. Research & Development
Immucell Corp.
966 Riverside Street
Portland, PIE 04103 Dr. Ruth
207-797-8386
TECHNOLOGIES:
MAJORPRODUCTS:
Purification (lab-scale), Hybridoma/cell fusion,
Cell/tissue culture, Large-scale purification
RPT(Rapid Progesterone Test)-cowside progesterone
in milk assay; RMT(Rapid Mastitls Test); RJT
(Rapid Johnes Test); group A streptococcal reagents
and tests
Dr. Ken Wldder, Chairman& CE0
Molecular Biosystems, Inc.
10030 Barnes CanyonRoad
San Diego, CA 92121 Dr. Wldden
619-452-0681
TECHNOLOGIES:
MAJORPRODUCTS:
Purification (lab-scale), Synthesis, Sequencing,
Emzymology
SNAP non-radloactive DNA probes for infectious
diseases; magnetic microspheres for cell sorting;
DNA synthesis supports; The Extractor nucleic acid
purification system; Albunex ultrasound contrast
agent.
PRODUCTS UNDER
DEVELOPMENT: klhunex ultrasound contrast agent; MRI contrast
agent; ultrasensitive probe detection systems.
Mr. Seth Rudwick, V. P. Product Development
Ortho Biotech
Route 202 (PO Box 300)
Rarltan, NJ 08869 Mr. Rudwick
201-218-7192
TECHNOLOGIES: Recombinant DNA, Fermentation, Purification
(lab-scale), Bioprocess, Hybridoma/cell fusion,
Cell/tissue culture, Large-scale purification,
Process Monitoring Control, Synthesis, Sequencing
MAJOR PRODUCTS:
PRODUCTS UNDER
DEVELOPMENT:
OKT3 (Orthoclone 0KT3), Timunox (thymopertin)
r-Hu-EPO, IL-2, hepatitis B, EGF, cancer monoclonal
antibodies
Dr. Robert M. Flora, VP-R&D
Pharmacia LKB Biotechnology, Inc.
800 Centennial Avenue
Piscataway, NJ 08854 Dr. Flora_
201-457-8000
TECHNOLOGIES:
MAJOR PRODUCTS:
Recombinant DNA, Fermentation, Purification
(lab-scale), Bloprocess, Hybrldoma/cell fusion,
Cell/tissue culture, Large-scale purification,
Process Monitoring Control, Synthesis, Sequencing,
Enzymology
FPLC and GTi chromatography systems and
instrument components; PhastSystem and
electrophoresls systems (Pulsaphor , Multlphor ),
Gene Assembler and Vlolynx syllthesyzers; FPLCpure
, restriction nucleasls; nucleic acids including
vectors; chromatography media including Sephadex ,
Sepharose , Sephacryl , MonoBeads , Superose ,
ultrafiltration products; large-scale bloprocessing.
Dr. Stephen M. Coutts
VP Therapeutic Research
Quidel
11077 North Torrey Plnes Rd.
La Jolla, CA 92037 Dr. Courts
619-450-1533
TECHNOLOGIES:
MAJOR PRODUCTS:
PRODUCTS UNDER
DEVELOPMENT:
Recombinant DNA, Purification (lab-scale),
Hybrldoma/cell fusion, Cell/tissue culture
Quidel pregnancy test, Ouidel ovulation test,
Quldel Strep Group A test, Quidel allergy screen,
Open Alert /Bovi-Pro 21 milk progesterone test
(distributed by Santel S.A.) QTEST pregnancy and
ovulation tests (distributed by BettoR, Dickinson
and Co.).
D-GL, suppressive factor of allergy; diagnostic
products; allergy, infectious disease assay
technologies, drug testing (TDM and DOA).
Dr. Jon A. RudBach
V. P. Research & Development
Ribi ImmunochemResearch, Inc.
P0 Box 1409
Hamilton, MT 59840 Dr. RudBach_
406-363-6214
TECHNOLOGIES:
MAJORPRODUCTS:
PRODUCTSUNDER
DEVELOPMENT:
Fermentation, Purification (lab-scale), Cell/tissue
culture, Large-scale purification, Synthesis
Ribigen veterinary anti-tumor product; Detox ,
humanantl-tumor, anti-viral product; Ovamid ,
humananti-tumor product; adjuvants (MPL, TDM);
research products (adjuvants, lipopolysaccharides,
mitogens, custom polyclonal sera).
Detox , in Phase II human clinical trials for
malignant melanoma, Kaposi's sarcoma, genital
warts; Ovamid , in Phase I human clinical trials
for ovarian cancer, human testing against
colorectal cancer planned; adjuvants for
non-speciflc resistance, malignant and infectious
disease vaccine applications
Mr. John J. Dingerdissen
Scientific Coordinator/Biotechnology Research
Smith Kllne & French Laboratories
PO Box 1539
King of Prussia, PA 19406-0939 Mr. Dingerdlssen_
215-270-7358
TECHNOLOGIES:
MAJOR PRODUCTS:
PRODUCTS UNDER
DEVELOPMENT:
Recombinant DNA, Fermentation, Purification
(lab-scale), Bloprocess, Hybridoma/cell fusion,
Cell/tissue culture, Large-scale purification,
Syrtthesls, Enzymology, Sequencing
Tagamet, Dyazide.
t-PA, rDNA malaria vaccine, leukotriene receptor
antagonist.
Dr. Claire T. Wake, Director
Technical Development
Synergen, Inc.
1885 33rd Street
Boulder, CO 80301 Dr. Hirsh
303-938-6270
TECHNOLOGIES:
PRODUCTS UNDER
DEVELOPMENT:
Recombinant DNA, Fermentation, Purification
(lab-sclence), Bioprocess, Cell/tissue culture,
Large-scale purification, Process Monitoring
Control, Synthesis, Sequencing, E_zymology
Protease inhlbitors (elastase inhibitor,
collagenase inhibitor), fibroblast growth factor
(FGF), vaccines for livestock, feed additives,
materials for tertiary oil recovery.
Terry Malone, Business DevelopmentManager
Triton Biosciences Inc.
1501 Harbor Bay Parkway
Almeda, CA 94501Mr. Malone_
415-769-5370
TECHNOLOGIES:
MAJORPRODUCTS:
PRODUCTSUNDER
DEVELOPMENT:
Recombinant DNA,Fermentation, Purification,
Hybridoma/cell fusion, Cell/tissue culture,
Synthesis, Sequencing
Antl-cytokeratin Mabs (MAK-6) , Ras-ha Abs.
TGF-alpha Abs. 8etaseron
Recombinant beta-interferon (Betaseron),
transforming factor-alpha, automated immunoassay
system, HTLV-I assay, cytokeratin assay, cancer
markers.
